Conditions: Hemophilia A
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 32
Healthy volunteers: no

Brief summary:
The goal of this study is to give gather more information on how safe and well Jivi works in patients with severe hemophilia A. Jivi has been approved by various regulatory agencies, including the FDA, Health Canada, Japanese Health Authority and the European Medicinal Agency. 25 patients will be enrolled and will stay for 1 to 2 years in this study depending on their treatment frequency. Researcher will monitor during the course of the study whether patients are developing antibodies (a protein made by the body in response to the drug) affecting the effectiveness of Jivi. In addition information on bleedings and patient's wellbeing will be collected.

Detailed description:

Arms:
arm 1: Prophylactic treatment regimens should be guided by clinical judgement based on individual patient characteristics and treatment response.

Interventions: intervention 1: Damoctocog alfa pegol (Jivi, BAY94-9027)
Intervention descriptions: intervention 1: The recommended starting dose is every 5 days treatment (45 IU/kg)- An assessment of response to treatment will be performed at the next scheduled visit after 10-15 ED (8-10 weeks). Participants may be assigned to different dosing regimens (every 7 days or 2x/week) or continue with every 5 days regimen, according to individual bleeding tendency and needs at investigator's discretion.

Protocol document:
Prot_000.pdf: 
 
Document Type: 
Study protocol 
Official Title: 
Post-marketing investigation (PMI) to assess safety and efficacy of 
Jivi (BAY 94-9027) treatment in patients with hemophilia A 
NCT Number: 
NCT04085458 
Document Date: 
04-Feb-2020 
 


CONFIDENTIAL
Integrated Clinical Study Protocol
BAY 94-9027 / 19764
Version 2.0
Page:  1 of 54
Title Page
Protocol Title: 
Post-marketing investigation (PMI) to assess safety and efficacy of Jivi (BAY 94-9027)
treatment in patients with hemophilia A 
Protocol Number:
19764
Amendment Number:
1
Compound Number:
BAY 94-9027 / Damoctocog alfa pegol; Human Pegylated 
rFVIII; Jivi®
Study Phase:
Phase IV
Short Title: Jivi interventional PMI study to assess safety and efficacy
Sponsor Name: Bayer Consumer Care AG
Legal Registered Address:
Bayer Consumer Care AG, Peter-Merian-Strasse 84, 4052 Basel, Switzerland
Regulatory Agency Identifier Number(s):
EudraCT: 2018-003655-37
Approval Date: 
04 FEB 2020
Confidential
The information provided in this document is strictly confidential and is intended solely for the performance of 
the clinical investigation.  Reproduction or disclosure of this document, whether in part or in full, to parties not 
associated with the clinical investigation or its use for any other purpose without the prior written consent of the 
sponsor is not permitted. 
Throughout this document, symbols indicating proprietary names (®, TM) may not be displayed for Jivi. 
However, the appearance of product names without these symbols does not imply that these names are not 
protected.


33'
33'
33'
PPD


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  3 of 54
Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document
Date
Amendment 1
04 FEB 2020
Original Protocol
19 MAR 2019
Amendment 1 (04 FEB 2020)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of the European Union, 
as it includes a new criterion for premature termination of the study.  Nevertheless, it neither 
significantly impacts the safety or physical/mental integrity of participants nor the scientific 
value of the study.
Overall Rationale for the Amendment:
This amendment was prepared to incorporate Health Authority feedback regarding the
definitions for both the end of study and adverse events, assess body weight at additional 
visits, and to clarify the number of times a participant may be rescreened.
Section # 
and Name
Description of Change
Brief Rationale
1.3 Schedule of Activities
8.2.2 Physical Examinations
10.4.4 Visit 4 – ED 50-75 (Month 
6 ± 14 days)
10.4.6 Visit 6 if needed – ED 50-
75 (Month 18 ± 14 days)
Body weight measurement 
has been added to Visits 4 
and 6.
Body weight will be assessed every 6 
months in order to avoid underdosing.
4.4 End of study definition
Definition for the end of the 
overall study changed The 
end of the overall study is 
defined as LPLV and the 
last data from the last visit 
are received.  For each 
participating country, end of 
study is achieved with 
LPLV in that country.
Align end of study with planned trial 
activities for participants.
4.4 End of Study Definition
Criteria added for premature
termination of the study.
Define stop criteria for premature
termination of the study. 
5.4 Screen Failures
Section updated to specify 
that screen failures may be 
rescreened once.
Define maximum number of times a 
participant may be rescreened.
6.2 Preparation/
Handling/Storage/Accountabilit
y
Instructions updated to more 
accurately describe the 
instructions for management 
of study intervention.
Reflects current sponsor standard.
10.1.1 Regulatory and Ethical 
Considerations
References to region-
specific laws removed
Remove redundancy, as these laws are 
covered by “...all other applicable local 
regulations.”


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  4 of 54
Section # 
and Name
Description of Change
Brief Rationale
10.2 Appendix 2: Clinical 
Laboratory Tests
Addition of 
albumin/creatinin ratio, 
Beta-2microglobulin.
Clarification that the biomarker 
albumin will be assessed through the 
albumin/creatinine ratio.  Beta-
2microglobulin was erroneously 
identified as alpha-2microglobulin.
10.3.1 Definition of AE
Requirements for laboratory 
test results modified
Agency request
10.3.4 Reporting of SAEs
Reporting instructions 
updated to refer to email 
instead of facsimile 
transmission.
Reflects current sponsor standard.
Typographical, grammatical, and other minor edits are not identified.


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  5 of 54
Table of Contents
Title Page................................................................................................................................... 1
Sponsor Signatory .................................................................................................................... 2
Protocol Amendment Summary of Changes Table............................................................... 3
Table of Contents...................................................................................................................... 5
Table of Tables.......................................................................................................................... 7
Table of Figures........................................................................................................................ 7
1.
Protocol Summary............................................................................................................. 8
1.1
Synopsis ........................................................................................................................... 8
1.2
Schema........................................................................................................................... 10
1.3
Schedule of Activities (SoA) ......................................................................................... 11
2.
Introduction ..................................................................................................................... 13
2.1
Study Rationale.............................................................................................................. 13
2.2
Background.................................................................................................................... 13
2.3
Benefit/Risk Assessment ............................................................................................... 14
3.
Objectives and Endpoints............................................................................................... 15
4.
Study Design .................................................................................................................... 15
4.1
Overall Design ............................................................................................................... 15
4.2
Scientific Rationale for Study Design............................................................................ 17
4.3
Justification for Dose ..................................................................................................... 17
4.4
End of Study Definition................................................................................................. 17
5.
Study Population ............................................................................................................. 18
5.1
Inclusion Criteria ........................................................................................................... 18
5.2
Exclusion Criteria .......................................................................................................... 19
5.3
Lifestyle Considerations ................................................................................................ 19
5.4
Screen Failures............................................................................................................... 19
6.
Study Intervention........................................................................................................... 20
6.1
Study Intervention(s) Administered............................................................................... 20
6.2
Preparation/Handling/Storage/Accountability............................................................... 21
6.3
Measures to Minimize Bias: Randomization and Blinding ........................................... 22
6.4
Study Intervention Compliance ..................................................................................... 22
6.5
Prior and Concomitant Therapy..................................................................................... 22
6.6
Dose Modification ......................................................................................................... 23
6.7
Intervention after the End of the Study.......................................................................... 23
7.
Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal.......................................................................................... 23
7.1
Discontinuation of Study Intervention........................................................................... 23
7.1.1
Temporary Discontinuation from Study Intervention ................................................ 24
7.2
Participant Discontinuation/Withdrawal from the Study............................................... 24
7.3
Lost to Follow Up .......................................................................................................... 25
8.
Study Assessments and Procedures............................................................................... 25
8.1
Efficacy Assessments..................................................................................................... 26
8.1.1
Treatment Logs/Bleeding Verification....................................................................... 26


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  6 of 54
8.1.2
Incremental Recovery of Jivi...................................................................................... 27
8.1.3
Activity Tracker.......................................................................................................... 28
8.2
Safety Assessments........................................................................................................ 28
8.2.1
Measurements of Immunogenicity ............................................................................. 28
8.2.2
Physical Examinations................................................................................................ 29
8.2.3
Vital Signs .................................................................................................................. 30
8.2.4
Clinical Safety Laboratory Assessments .................................................................... 30
8.3
Adverse Events and Serious Adverse Events ................................................................ 31
8.3.1
Time Period and Frequency for Collecting AE and SAE Information....................... 31
8.3.2
Method of Detecting AEs and SAEs .......................................................................... 31
8.3.3
Follow-up of AEs and SAEs....................................................................................... 31
8.3.4
Regulatory Reporting Requirements for SAEs........................................................... 32
8.3.5
Pregnancy ................................................................................................................... 32
8.3.6
Disease-Related Events and/or Disease-Related Outcomes Not Qualifying as AEs 
or SAEs....................................................................................................................... 32
8.3.7
Events of Special Interest ........................................................................................... 33
8.4
Treatment of Overdose................................................................................................... 33
8.5
Pharmacokinetics ........................................................................................................... 33
8.6
Pharmacodynamics ........................................................................................................ 33
8.7
Genetics.......................................................................................................................... 33
8.8
Biomarkers..................................................................................................................... 33
8.9
Other investigations ....................................................................................................... 34
8.10
Health Economics OR Medical Resource Utilization and Health Economics .............. 34
9.
Statistical Considerations ............................................................................................... 34
9.1
Statistical Hypotheses .................................................................................................... 34
9.2
Sample Size Determination............................................................................................ 34
9.3
Populations for Analyses ............................................................................................... 35
9.4
Statistical Analyses ........................................................................................................ 35
9.4.1
Efficacy Analyses ....................................................................................................... 35
9.4.2
Safety Analyses .......................................................................................................... 36
9.5
Interim Analyses ............................................................................................................ 36
10. Supporting Documentation and Operational Considerations .................................... 37
10.1
Appendix 1: Regulatory, Ethical, and Study Oversight Considerations........................ 37
10.1.1
Regulatory and Ethical Considerations ...................................................................... 37
10.1.2
Financial Disclosure ................................................................................................... 37
10.1.3
Informed Consent Process.......................................................................................... 38
10.1.4
Data Protection ........................................................................................................... 38
10.1.5
Dissemination of Clinical Study Data ........................................................................ 38
10.1.6
Data Quality Assurance.............................................................................................. 39
10.1.7
Source Documents...................................................................................................... 40
10.1.8
Study and Site Closure ............................................................................................... 40
10.1.9
Publication Policy....................................................................................................... 40
10.2
Appendix 2: Clinical Laboratory Tests.......................................................................... 41
10.3
Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting .............................................................................................. 42
10.3.1
Definition of AE ......................................................................................................... 42
10.3.2
Definition of SAE....................................................................................................... 44
10.3.3
Recording and Follow-Up of AE and/or SAE............................................................ 45


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  7 of 54
10.3.4
Reporting of SAEs...................................................................................................... 46
10.4
Appendix 4: Visit Description ....................................................................................... 47
10.4.1
Visit 1 – Screening (Approximately 2 to 8 Weeks).................................................... 47
10.4.2
Visit 2 – Baseline Predose (Day 1)............................................................................. 48
10.4.3
Visit 3 – ED 10-15 (Week 8-10) ................................................................................ 49
10.4.4
Visit 4 – ED 50-75 (Month 6 ± 14 days).................................................................... 50
10.4.5
Visit 5 – ED 50-75 (Month 12 ± 14 days).................................................................. 50
10.4.6
Visit 6 if needed – ED 50-75 (Month 18 ± 14 days) .................................................. 51
10.4.7
Last Visit – ED 100 (End of Study/Early Termination + 14 days) ............................ 51
10.5
Appendix 5: Abbreviations............................................................................................ 53
11. References ........................................................................................................................ 54
Table of Tables
Table 1–1 Study Schedule of Activities (SoA) ........................................................................ 11
Table 10–1: Protocol-Required Safety Laboratory Assessments............................................. 41
Table of Figures
Figure 1–1 Schema for suggested dose changes in response to bleeding ................................ 10


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  8 of 54
1.
Protocol Summary
1.1
Synopsis
Protocol Title:
Post-marketing investigation (PMI) to assess safety and efficacy of Jivi 
(BAY 94-9027) treatment in participants with hemophilia A 
Short Title:
Jivi interventional study to assess safety and efficacy
Rationale:
This study aims to collect clinical data in at least 25 participants, to 
comply with the post-marketing requirements to collect safety data of 
200 participants treated with at least 100 exposure days (ED) including 
participants from pre-authorization studies, according to EMA FVIII 
guideline requirements EMA/CHMP/BPWP/144533/2009 rev.2 (EMA 
2017).
Objectives and Endpoints:
Objectives
Endpoints throughout the study
Primary

To assess safety of Jivi 
Primary Endpoint  

FVIII inhibitor development by the 
Nijmegen Bethesda assay. 
Secondary Endpoints

Treatment-emergent adverse events 
(TEAE)

Development of treatment-emergent anti-
PEG antibodies
Secondary

To assess clinical efficacy of Jivi 
Secondary Endpoint

Annualized bleeding rate (ABR) 
Overall Design:
The study will be a multicenter, single group, uncontrolled open-label trial. Severe hemophilia 
A patients, age ≥18 years, will be enrolled and treated with prophylaxis treatment and for 
breakthrough bleeds for at least 100 exposure days (ED), which may require 1-2 years 
depending on the prophylaxis regimen. Assessment of immunogenicity/safety will be 
performed at pre-defined ED as required by the EMA FVIII Guideline. The recommended 
starting dose is every 5 days treatment (45 IU/kg). Response to treatment will be assessed at 
the next visit after 10-15 ED, scheduled for inhibitor assessment as per Guideline. Participants 
may be assigned to different dosing regimens (every 7 days or 2x/week) or continue with 
every 5 days regimen, according to individual bleeding tendency and needs at investigator’s 
discretion. Clinical general safety, efficacy, and immunogenicity will be assessed at baseline, 
10-15 ED, 50-75 ED and after approximately 100 ED.
This study will address regulatory requirements of assessment of safety in a total of 200 
participants with 100 ED including pre-licensure participants of the development program 
from the studies #13024 Protect VIII and #15912 Protect Kids. This study will include at least 
25 participants for fulfillment of the requirement and provide a pooled analysis of all clinical 
studies (phase III/IV) including at least 200 participants observed for at least 100 ED. 
The study will assess the important identified risks of development of Factor VIII (FVIII) 
inhibitors, hypersensitivity, and potential lack of drug effect associated with anti-polyethylene 
glycol (PEG) antibodies during the first exposures to Jivi and long-term treatment up to 100 


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  9 of 54
ED. An optional interim analysis will be performed, if needed for regulatory submission or 
publication purposes, after all participants have been treated for 6 months.
Intervention Model: Single Group
Primary Purpose:
Treatment
Number of Arms:
Single arm
Masking:
No masking
Number of Participants: Approximately 25-30 participants will be assigned to the study 
intervention. At least 25 participants are expected to complete the study. The study is 
completed when 25 participants have reached 100 ED.
Intervention Groups and Duration: 
All participants will be treated with three possible prophylactic regimens: 2x/week, every 5 
days, or every 7 days with a recommended starting regimen of every 5 days. Participants are 
allowed to change the dose frequency during the study. All treatment decisions for identifying 
appropriate prophylactic treatment regimens should be guided by clinical judgement based on 
individual participant characteristics and treatment response. 
The total treatment duration is the time to reach 100 exposure days (ED) of Jivi. The total 
duration of study participation for each participant may require up to 2 years depending on the 
selected prophylactic regimen. After the end of the study, the participants will be offered the
option to participate in a non-interventional PASS study. While the decision for dose 
adjustment is at the investigator’s discretion based on patient clinical characteristics, the 
following recommendations are provided: the starting dose is 45 IU/kg every 5 days. 
Investigator may assess if dose regimen adjustment is warranted at the next planned visit (10-
15 ED). A participant with zero bleed during the first 8-10 weeks of treatment may be 
considered for every 7 days at 60 IU/kg; a participant with 1 clinically relevant bleed during 
the first 8-10 weeks may be considered to either continue treatment every 5 days while at the 
60 IU/kg or switch to twice weekly at 40 IU/kg; and a participant with ≥ 2 clinically relevant 
bleeds during the first 8-10 weeks should be changed to twice weekly at 40 IU/kg.
The details about duration and recommended dose regimen of study participation are as 
follows:


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  10 of 54
Recommended dose regimen
Procedure
Duration
Dose regimen
Route of 
administration
Screening
> 2 weeks,
≤8 weeks
Continuation of previous treatment
Treatment 
Phase
Time to 
reach 10-
15 ED (8 to 
10 weeks)
Recommended starting dose 45 IU/kg every 5 
days.  Dose regimen can be adjusted any time 
in case of bleeds 
IV injection
Time to 
reach 100 
ED
0 bleed 
during the 
first 8-10 
weeks: 
Recommended dose regimen: 
60 IU/kg every 7 days
IV injection
1 clinically 
relevant 
bleed during 
the first 8-10 
weeks:
Continue every 5 days at dose 
of 60 IU/kg
Or at investigator’s judgement: 
Switch to 40 IU/kg 2x/week 
≥ 2 clinically 
relevant 
bleeds during 
the first 8-10 
weeks:
Change to 40 IU/kg 2x/week
ED = exposure day, IV = intravenous 
Clinically relevant: joint or muscle bleed that need treatment
Data Monitoring Committee:
No
1.2
Schema
Figure 1–1 Schema for suggested dose changes in response to bleeding


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
           Page:  11 of 54
1.3
Schedule of Activities (SoA)
Table 1–1 Study Schedule of Activities (SoA)
Procedures
Screening a
Baseline 
Pre-dose
ED 10-15
ED 50-75 
Every 6 months
End of study
100 ED / Early 
Termination
Visit 1
2-8 Wks
before 
baseline
Visit 2 
Day 1
Visit 3
Wk 8-10 b
Visit 4 
Month 6 
(±14 days) c
Visit 5 
Month 12 
(±14 days) c
Visit 6
Month 18 
if needed 
(±14 days) c
Last Visit
(+14 days)
Informed consent (inclusion )
X
HIV screening d
X
Inclusion and exclusion criteria
X
X
Demography(including gene defect)
X
Full physical examination including neurological 
standard assessment, height, and weight
X
X
Body Weight Measurement 
X
X
X
Activity level (type of sports, hrs/wk)
X
Medical and surgical history (general, disease, 
family history of hemophilia, and history of inhibitor)
X
Activity tracker
X
X
X
X
X e
Previous medication (medication history)
X
Dose regimen adjustment
X
Vital signs f
X
X
X
Urine sample (routine urinalysis and renal 
biomarkers)
X
X
X
X
Laboratory assessments (Hematology and clinical 
chemistry,)
X
X
X
PEG level in plasma
X
X
Immunogenicity (Factor VIII inhibitor, ADA) g
X
X
X
X
X
X


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
           Page:  12 of 54
Table 1–1 Study Schedule of Activities (SoA)
Procedures
Screening a
Baseline 
Pre-dose
ED 10-15
ED 50-75 
Every 6 months
End of study
100 ED / Early 
Termination
Visit 1
2-8 Wks
before 
baseline
Visit 2 
Day 1
Visit 3
Wk 8-10 b
Visit 4 
Month 6 
(±14 days) c
Visit 5 
Month 12 
(±14 days) c
Visit 6
Month 18 
if needed 
(±14 days) c
Last Visit
(+14 days)
Recovery (pre and 15-30 min post injection FVIII 
levels) h
X
X
X
FVIII level after 48 or 72 hours after last injection
X
X
In-hospital injection of Jivi
X
X
X
AE review
X
X
X
X
X
X
X
Return used and unused study intervention
X
X
X
X
X
Dispense study intervention for home injections
==continuously in accordance with IxRS drug dispensing schedule==
Injection of Jivi
====continuously in accordance with assigned treatment regimen===
Concomitant medication review 
X
====================continuously=======================
Patient diary (EPD) documentation
X
====================continuously=======================
Interaction between participants and investigators
====================Monthly contact=====================
Abbreviations: ADA=anti-drug antibody, AE=adverse event, ALT=alanine aminotransferase, AST=aspartate aminotransferase, ED=exposure 
days, EPD=electronic patient diary, HIV=human immunodeficiency virus, hrs=hours, IxRS=Interactive voice/web response system, 
max=maximum, and Wk=week.
a.
The time interval between Screening and Baseline visit is 2 to 8 weeks. 
b.
Although the allowable visit window is ±14 days, visits must occur within the specified ED range. 
c.
Visits should be scheduled within the visit window so that at least one visit occurs in the 50 – 75 ED range.
d.
HIV screening will be performed only in case that negative result in patient documentation is older than 1 year at date of screening.
e.
Only in case of Early Termination Visit before V6.
f.
In case of any injection related AE, vital signs will be collected in addition post-injection for participants.
g.
At Baseline, Visit 3 and End of Study/Early Termination Visit, blood samples for immunogenicity will be collected before the in-hospital 
injection of Jivi.
h.
Recovery should be measured at least 72 h after last injection of FVIII of Jivi.


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  13 of 54
2.
Introduction
Recombinant coagulation FVIII (rFVIII) is a replacement therapy in patients with 
Hemophilia A. 
Jivi (BAY 94-9027) is a recombinant B-domain deleted (BDD) human coagulation FVIII 
variant expressed in a baby hamster kidney cell line and site specifically conjugated with a 60 
kDa, branched (30 kDA each) polyethylene glycol (PEG). Jivi was developed as an extended 
half-life recombinant FVIII (rFVIII) through PEGylation resulting in a reduced clearance 
from plasma while retaining the normal activity of the FVIII molecule.
Jivi has received marketing authorization from Food and Drug Administration (FDA), 
European Medicines Agency (EMA), Japanese Pharmaceuticals and Medical Devices Agency 
(PMDA), and Health Canada. The approved indication is: Treatment and prophylaxis of 
bleeding (including perioperative management) in previously treated patients (PTPs) ≥ 12 
years of age with hemophilia A (congenital FVIII deficiency).
2.1
Study Rationale
Hemophilia A is caused by deficiency or reduced activity of Factor VIII, a critical component 
of blood coagulation.
Hemophilia A patients are treated by intravenous administration of FVIII on-demand or as a 
prophylactic therapy administered two to four times a week with unmodified FVIII products.
The need for frequent intravenous injection creates barriers to patient compliance and makes
adherence to prophylaxis difficult. Treatment with FVIII products with extended half-life 
(EHL) are expected to result in significant benefit in long-term outcomes and quality of life 
improvement for patients with hemophilia. Products with an extended t1/2 have been 
approved recently in several countries worldwide (such as Elocta®, Eloctate®, Adynovate®) 
which provide treatment options with dosing intervals of 3 to 5 days for prophylaxis 
treatment.
Jivi was developed as an EHL- FVIII for prophylaxis, peri-operative management, and 
treatment of acute bleeding events. Site directed PEGylation was used to increase the FVIII 
half-life, resulting in a longer duration of the effect by raising plasma levels for a longer 
duration, thereby allowing for less frequent dosing when used in a prophylaxis setting.
Efficacy and safety of Jivi were demonstrated in the pivotal trials (Coyle et al. 2014, Reding 
et al. 2017).
This study aims to collect clinical data in at least 25 participants, to comply with the post-
marketing requirements to collect safety data of 200 participants treated with at least 100 ED 
including participants from pre-authorization studies, according to the EMA FVIII guideline 
requirements EMA/CHMP/BPWP/144533/2009 rev.2 (EMA 2017).
2.2
Background
Individuals with severe hemophilia A (<1% functional FVIII) experience frequent and 
recurrent bleeding into the soft tissue and joints, resulting in joint damage and destruction, as 
well as significant negative effects on their Quality of life (QoL), psychosocial well-being, 
education, and financial condition. Factor replacement therapy is used to treat bleeding events 


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  14 of 54
when they occur. However, such “on-demand” therapy is insufficient for the prevention of 
arthropathy (Aledort et al. 1994, Petrini et al. 1991). International treatment guidelines 
recommend that all individuals with severe hemophilia should be treated with some form of 
prophylactic therapy. The efficacy of standard regimens in preventing bleeding events has 
been confirmed by multiple observational studies (Aledort et al. 1994, Ljung 1998, Lofqvist 
et al. 1997, Nilsson et al. 1992), and the value of regular infusion starting in early childhood 
in preventing joint damage was recently confirmed objectively (Manco-Johnson et al. 2007). 
Despite recommendations by the World Health Organization (WHO) and World Federation of 
Hemophilia that prophylaxis should be the standard of care; such treatment has not been 
uniformly accepted by patients for different reasons. One of the reasons is that the prophylaxis 
is a time consuming and demanding regimen. In addition, adherence to a regularly scheduled 
regimen that requires intravenous infusion as often as 3x/week is difficult to maintain.
Jivi was developed as an extended half-life rFVIII through PEGylation resulting in a reduced 
clearance from plasma while retaining the normal activity of the FVIII molecule. 
Pharmacokinetics (PK) studies with Jivi demonstrated a prolonged half-life and improved 
area under the curve (AUC) as compared to unmodified FVIII(Coyle et al. 2014). Clinical 
efficacy and safety for treatment of bleeds and prophylaxis with 2x/week, every 5 days, and 
every 7 days have been evaluated in the clinical development program including 232 patients 
in the age of 2-65 years. Jivi has received market authorization approval for treatment and 
prophylaxis of bleeding in previously treated patients ≥ 12 years of age with hemophilia A 
(congenital factor VIII deficiency).
Further information on efficacy and safety of Jivi is provided in the Summary of Product 
Characteristics (SmPC).
2.3
Benefit/Risk Assessment
Jivi has received marketing authorization by the FDA, EMA, PMDA, and Health Canada for 
the treatment and prevention of bleeds in patients ≥12 years of age.
Jivi has demonstrated the potential for dosing every 5 days or every 7 days in a majority of 
participants in clinical studies, offering the option of a prophylaxis treatment with less 
frequent dosing for hemophilia A patients ≥ 12 years of age.  For the patients with increased 
bleeding tendency, 2x/week treatment with Jivi provided an efficacious treatment option. 
As is the case for all FVIII replacement treatments, the most serious expected adverse event 
(AE) is the development of inhibitory antibodies against FVIII. No new or confirmed 
inhibitors have been observed during the clinical studies.
Hypersensitivity reactions are a known and listed adverse event for FVIII products and have 
been reported with use of Jivi. A clinical immune response associated with anti-PEG 
antibodies, manifested as symptoms of acute hypersensitivity and/or loss of drug effect has 
been observed within the first 4 exposure days primarily in children < 6 years of age (Study 
#15912 PROTECT Kids). 
 
 in 
such cases Jivi should be discontinued and patients switched to a previously effective 
factor VIII product.
CCI


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  15 of 54
Based on available data and considering the medical need, the benefit risk assessment was 
considered to be positive by Regulatory Authorities.
More detailed information about the known risks and reasonably expected adverse events of 
Jivi may be found in the SmPC/ Package Leaflet.
3.
Objectives and Endpoints
The objective of the study is to confirm general safety and clinical efficacy with specific focus 
on immunogenicity and inhibitor documentation in a routine clinical use of the product in at 
least additional 25 participants during 100 ED in order to fully comply with Guideline 
requirements of 200 participants observed for at least 100 ED including participants from pre-
authorization studies.
Objectives
Endpoints throughout the study
Primary
!
To assess safety of Jivi
Primary Endpoint  
!
FVIII inhibitor development by the 
Nijmegen Bethesda assay. 
Secondary Endpoints
!
Treatment-emergent adverse events 
(TEAE)
!
Development of treatment-emergent 
anti-PEG antibodies
Secondary
!
To assess clinical efficacy of Jivi
Secondary Endpoint
!
Annualized bleeding rate (ABR) 
Other pre-specified
!
Other pre-specified endpoints are 
specified in statistical analysis plan 
(SAP)
Other pre-specified
!
 
 
 
 
!
 
 
4.
Study Design
4.1
Overall Design
The study will be a multicenter, single group, uncontrolled open label trial. Severe hemophilia 
A patients, age ≥18 years, will be enrolled and treated with prophylaxis treatment and for 
breakthrough bleeds for at least 100 ED, which may require 1-2 years depending on the 
CCI
CCI


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  16 of 54
prophylaxis regimen. Assessment of immunogenicity/safety will be performed at pre-defined 
ED as required by EMA FVIII Guideline. 
The recommended starting dose is every 5 days treatment (45 IU/kg)- An assessment of 
response to treatment will be performed at the next scheduled visit after 10-15 ED (8-10
weeks). Thereafter, participants may be assigned to different dosing regimens (every 7 days or 
2x/week) or continue with every 5 days regimen, according to individual bleeding tendency 
and needs at investigator’s discretion. Clinical general safety, efficacy, and immunogenicity 
will be assessed at baseline, after 10-15 ED, 50-75 ED and after approximately 100 ED.
This study will address regulatory requirements of assessment of safety in a total of 200 
participants with 100 ED including pre-licensure participants of the development program 
from the studies #13024 Protect VIII and #15912 Protect Kids. This study will include at least 
25 participants for fulfillment of the requirement and provide a pooled analysis of all clinical 
studies (phase III/IV) including at least 200 participants observed for at least 100 ED. 
The study will assess the important identified risks of development of Factor VIII (FVIII) 
inhibitors, hypersensitivity, and potential lack of drug effect associated with anti-polyethylene 
glycol (PEG) antibodies during the first exposures to Jivi and long-term treatment up to 100 
ED.
Intervention Groups and Duration:
Participants will be enrolled in the study and start the recommended starting treatment with 
every 5 days at a dose of 45 IU/kg. Participants with an increase in bleeding frequency may 
switch to a twice weekly regimen (2x/week, 40 IU/kg) at the investigator’s discretion during 
the first 8-10 weeks.
At the next scheduled visit (after 10-15 ED, 8-10 weeks), all participants will have their 
bleeding frequencies reviewed by the investigator to determine any adjustment of the
treatment. Participants who have no bleeds during the first 8-10 weeks are recommended to 
have the treatment with every 7 days at a dose of 60 IU/kg. Participants who have 1 clinically 
relevant bleed (e.g. joint or muscle bleed) during the first 8-10 weeks may continue the 
treatment with every 5 days at dose of 60 IU/kg; the regimen may also be adjusted to 2x/week 
(40 IU/kg) at the investigator’s discretion after evaluation of bleed risk. If participants have ≥ 
2 relevant bleeds during the first 8-10 weeks, these participants should change treatment to 40 
IU/kg 2x/week. For overweight patients, the maximum total dose per injection should not be 
higher than approximately 6000 IU (rounded up to full vials).
Participants are allowed to change the dose frequency at any time during the study in case of 
increase in bleeding frequency. All treatment decisions for identifying appropriate 
prophylactic treatment regimens should be guided by clinical judgement based on individual 
participant characteristics and treatment response. It is recommended that the participant
increases frequency (if treated every 7 days or every 5 days) after a second spontaneous bleed 
within a 3-month period.
The total treatment duration is the time to reach 100 (exposure days) ED of Jivi. The total 
duration of study participation for each participant may require up to 2 years depending on the 
selected prophylactic regimen. The details about duration and recommended dose regimen of 
study participation for each study periods are as follows:


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  17 of 54
Procedure
Duration
Dose regimen
Route of 
administration
Screening
> 2 weeks, 
≤ 8 weeks
Continuation of previous treatment
Treatment 
Phase
Time to 
reach 10-
15 ED (8 to 
10 weeks)
Recommended starting dose 45 IU/kg every 5 
days.  Dose regimen can be adjusted any time 
in case of bleeds 
IV injection
Time to 
reach 100 
ED
0 bleed 
during the 
first 8-10 
weeks: 
Recommended dose regimen: 
60 IU/kg every 7 days
IV injection
1 clinically 
relevant 
bleed during 
the first 8-10 
weeks:
Continue every 5 days at dose 
of 60 IU/kg
Or at investigator’s judgement: 
Switch to 40 IU/kg 2x/week 
≥ 2 clinically 
relevant 
bleeds during 
the first 8-10 
weeks:
Change to 40 IU/kg 2x/week
ED = exposure day, IV = intravenous 
Clinically relevant: joint or muscle bleed that need treatment
4.2
Scientific Rationale for Study Design
The study is designed according the requirements defined in the “Guideline on the clinical 
investigation of recombinant and human plasma-derived factor VIII products” 
EMA/CHMP/BPWP/144533/2009 rev.2 (EMA 2017). The total sample size was chosen in 
order to fulfil Guideline requirements of 200 participants observed for at least 100 ED.
4.3
Justification for Dose
The dose is based on the SmPC.
Prophylactic treatment regimens should be guided by clinical judgement based on individual 
patient characteristics and treatment response.
4.4
End of Study Definition
A participant is considered to have completed the study if he has completed all phases of the 
study including the last visit or the last scheduled procedure shown in the Schedule of 
Activities. If more than 25 participants are included, all participants will be treated for at least 
6 months, but not all participants may reach 100 ED at the end of the study.


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  18 of 54
The end of the clinical trial in each participating country is achieved with LPLV in the 
country.  The end of the overall study is defined as LPLV and the last data from the last visit 
are received.1
Primary completion
The primary completion is defined as the date when 25 participants have completed the last 
visit for the primary outcome.
Premature termination of study
The trial must be stopped if new safety information emerges that can negatively affect the 
benefit/risk assessment of Jivi or the clinical trial.
5.
Study Population
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known 
as protocol waivers or exemptions, is not permitted.
At least 25 participants will be included. Medical record to a detailed participant 
documentation (ie, diary, etc.) covering either the last 150 exposure days or the last 2 years 
per participant to confirm treatment modality (i.e. prophylaxis, on demand), should be 
available.
5.1
Inclusion Criteria
Participants are eligible to be included in the study only if all of the following criteria apply:
Age
1. Participants must ≥ 18 years of age inclusive, at the time of signing the informed 
consent
Type of Participant and Disease Characteristics
2. Participants with severe hemophilia A (FVIII: C<1%)
3. PTPs (≥150 ED) on prophylaxis treatment before enrollment
4. Participants who are immunocompetent. If human immunodeficiency virus (HIV) 
positive, cluster of differentiation 4 (CD4)+ lymphocyte count >200/mm3  
5. Participants who are willing to complete an eDiary
Sex
6. Male participants 
                                                
1 Following LPLV, lab result data (e.g. inhibitor results, clinical chemistry, hematology) must be received before 
the study can be considered completed.


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  19 of 54
Informed Consent
7. Capable of giving signed informed consent as described in Section 10.1.3 of the 
protocol which includes compliance with the requirements and restrictions listed in 
the informed consent form (ICF) and in the protocol
5.2
Exclusion Criteria 
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions
1. Any other inherited or acquired bleeding disorder in addition to Hemophilia A.
2. Platelet count < 100,000/mm3
3. Creatinine > 2x upper limit of normal
4. AST or ALT > 5x upper limit of normal (AST: aspartate aminotransferase; ALT: 
alanine aminotransferase)
Prior/Concomitant Therapy
5. The participant has a planned major surgery. 
Prior/Concurrent Clinical Study Experience
6. The participant is currently participating in another investigational drug study, or has 
participated in a clinical study involving an investigational drug within 30 days of 
signing informed consent or previous treatment in a clinical phase III study with 
BAY 94-9027
Diagnostic assessments
7. Current evidence (by central laboratory) or history of inhibitor to FVIII with a titer ≥ 
0.6 Bethesda unit (BU).
Other Exclusions
8. Known hypersensitivity to the drug substance, excipients, or mouse or hamster 
protein.
5.3
Lifestyle Considerations
No restrictions are required. 
5.4
Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently entered in the treatment phase of the study. A minimal set of screen 
failure information is required to ensure transparent reporting of screen failure participants to 
meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements 


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  20 of 54
and to respond to queries from regulatory authorities. Minimal information includes 
demography, screen failure details, eligibility criteria, and any serious adverse event (SAE).
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened once, and repeat the screening procedures/laboratory tests provided that all 
screening procedures/laboratory tests are performed within the 8-week screening period.
Rescreened participants should be assigned a new participant number.
6.
Study Intervention
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant according to 
the study protocol.
6.1
Study Intervention(s) Administered
All treatment decisions for identifying appropriate prophylactic treatment regimens should be 
guided by clinical judgment based on the approved SmPC and the individual participant
characteristics and treatment response:
Treatment
Every 5 days
2x/week
Every 7 days
Intervention Name
Jivi 
Type
Biologic
Dose formulation
Ampule
Duration of 
intervention
Up to 100 ED, regimen as per investigator decision
Unit dose 
strengths
500, 1000, 2000, or 3000 IU/vial 
Dosage Level(s)
45-60 IU/kg
Every 5 days
The total recommended 
maximum 
dose/injection is 
approximately 6000 IU 
(rounded up to vial 
size).
40 IU/kg
Two times per week
60 IU/kg
Every 7 days
The total 
recommended 
maximum 
dose/injection is 
approximately 6000 IU 
(rounded up to vial 
size).
Route of 
Administration
IV injection
IMP and NIMP
IMP (Jivi)
Sourcing
Provided by the Sponsor 
Packaging and 
Labeling
Jivi will be provided in glass vials with a prefilled syringe.  Each glass vial 
will be labeled as required per country requirement.
Current Name / 
Former Name
Commercial name: Jivi / BAY 94-9027
ED=exposure day, IMP=Investigational medicinal product, NIMP= Non investigational medicinal 
product


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  21 of 54
Treatment of bleeds 
All bleeding events that occur in participants receiving prophylactic infusion after the start of
treatment (Visit 2) will be treated with Jivi as outlined in the package insert (SmPC). If a 
bleed occurs on a day of the planned injection, the participant should treat the bleed instead of
receiving the scheduled prophylactic infusion.
The infusion schedule with Jivi is not affected by the treatment of bleeds, eg, if a participant
treats a bleed on Sunday and is due to infuse his prophylactic dose on Monday, he will still 
receive the scheduled infusion. If a repeated treatment for the bleed is required, the dose
administered on the scheduled infusion day may be modified to ensure the participant receives
appropriate treatment.
6.2
Preparation/Handling/Storage/Accountability
Instructions for the preparation of study interventions can be found in the leaflet for using 
Jivi.
All study interventions will be stored at the investigational site in accordance with Good 
Clinical Practice (GCP) and Good Manufacturing Practice (GMP) requirements and the 
instructions given by the clinical supplies department of the sponsor or its affiliates. 
Special storage conditions and a complete record of batch numbers and expiry dates can be 
found in the sponsor’s study file; the site-relevant elements of this information will be 
available in the investigator site file. On the day of receipt, the responsible site personnel will 
confirm receipt of study intervention via IxRS.
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study intervention received and any 
discrepancies are reported and resolved before use of the study intervention.
2. Only participants enrolled in the study will receive study intervention and only 
authorized site staff will supply or administer study intervention. All study 
intervention must be stored in a secure, environmentally controlled, and monitored 
(manual or automated) area in accordance with the labeled storage conditions with 
access limited to the investigator and authorized site staff.
3. The investigator, or the head of the institution (where applicable) is responsible for 
study intervention accountability, reconciliation, and record maintenance (i.e., receipt, 
reconciliation, and final disposition records).
4. Further guidance and information for the final disposition of unused study 
interventions are provided in a separate document.


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  22 of 54
6.3
Measures to Minimize Bias: Randomization and Blinding
This is an open-label study, and no randomization or masking will be performed.
Participants will be identified by a unique participant number with 9 digits once the ICFs are 
signed. The first 5 digits will identify the country and study site, the last 4 digits are assigned 
to the participant of the specific site in increasing order. 
6.4
Study Intervention Compliance
Participant compliance with study intervention will be assessed at each visit.
Used and unused vials of study medication will be returned to the clinic at every site visit for 
accounting. Any discrepancies between actual and expected amount of returned vials must be 
discussed with the participant at the time of the visit, and any explanation must be 
documented in the source records.
The electronic patient diary (EPD) will be used to assess the participant’s compliance with the 
treatment schedule/dose, and to reconcile study medication inventory. The EPD will be used 
to record date and time of self-administration of study intervention for prophylaxis as well as 
every bleeding episode with details of the bleeding and administered intervention. Data on the 
EPD will be transmitted on a regular basis.
The EPD will be reviewed at visits and at regular contacts with the participant during the 
study.
6.5
Prior and Concomitant Therapy
Any medication or vaccine (including over-the-counter or prescription medicines, vitamins, 
and/or herbal supplements) that the participant is receiving at the time of enrollment or 
receives during the study must be recorded along with:

Reason for use

Dates of administration including start and end dates

Dosage information including dose and frequency
The Medical Monitor (Study Medical Expert) should be contacted if there are any questions 
regarding concomitant or prior therapy.
Bleeds which occur during the screening period (Screening visit until Visit 2) will be treated 
with the participant’s previous FVIII product.
All medications and blood products required by the participant after the informed consent is 
signed, including FVIII products other than study intervention, will be listed in the 
appropriate CRF. All concurrent prescription and non-prescription medications including 
over-the-counter and alternative preparations (including herbal remedies, vitamins, and health 
food supplements), antibiotics and pain medications being administered starting at least 3 


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  23 of 54
months previous to the study will be recorded in the CRF at screening and throughout the 
treatment and follow-up periods.
The participant should not be taking any other investigational drug while receiving treatment 
with Jivi.
Medications which cause a bleeding diathesis (for example, Aspirin® or any acetylsalicylic 
acid) should be avoided in individuals with hemophilia, except as specifically prescribed by a 
treating physician. Low dose Aspirin should not be discontinued in participants who have 
been identified to be at risk for cardiovascular events. The decision to prescribe non-steroidal 
anti-inflammatory drugs, Cyclooxygenase-2 (COX-2) inhibitors, or brief courses of 
corticosteroids to treat pain or acute synovitis is at the discretion of the treating physician. 
Inhaled or topical steroid medications (as for the treatment of asthma or eczema) are allowed. 
Brief courses of prednisone/methylprednisolone (< 14 days) for treatment of disorders such as 
synovitis, asthma, etc. are at the discretion of the treating physician. For any participant
requiring longer courses of corticosteroids or use of other immunomodulatory treatment, the 
investigator should notify the sponsor.
6.6
Dose Modification
This protocol allows some alterations from the currently outlined dosing schedule, but the 
maximum dose must not exceed approximately 60 IU/kg for every 5 days and every 7 days 
treatments and approximately 40 IU/kg for 2x/week treatment, and for patients with 
overweight, the dose per injection should not be higher than approximately 6000 IU, rounded
up to full vials. Dose adaptations according to participant needs and at the investigator’s 
discretion are allowed within the approved dose range and rounding up to full vials which 
may result in slightly higher dosages.
6.7
Intervention after the End of the Study
After completion of the study, treatment with study intervention will end. Subsequent 
treatment will be mutually agreed upon by the participants and the investigator. 
7.
Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal 
7.1
Discontinuation of Study Intervention 

Inhibitor development
Any inhibitor development (≥0.6 BU/mL, confirmed) is considered a SAE. 
Discontinuation of study intervention due to a high titer inhibitor development (titer > 
5 NBU/mL) should be considered by the investigator if the investigator believes that it 
is in the best interest of the participant and/or if bypassing agents are needed to treat 
bleeds. Participants who discontinue study intervention due to inhibitor development 
cannot continue in the study and will be withdrawn.


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  24 of 54

Planned major surgery during the study
If the participant has a planned elective surgery during the study, the investigator and 
sponsor will determine if the participant can continue in the study and if any change in 
participant management is needed.
See the SoA for data to be collected at the time of intervention discontinuation and for any 
further evaluations that need to be completed. 
7.1.1
Temporary Discontinuation from Study Intervention
Participants who have an elective major surgery during the study may be treated with other 
FVIII, according to local practice at the discretion of investigators. Participants will resume 
their treatment assignment of Jivi as per this protocol after surgical recovery.
7.2
Participant Discontinuation/Withdrawal from the Study
A participant who withdraws is one who discontinues from a clinical study for any reason. 
The participant will not suffer any disadvantage as a result.

A participant may withdraw from the study at any time at his own request without 
giving reasons, or may be withdrawn at any time at the discretion of the investigator 
for safety, behavioral, compliance, or administrative reasons..

At the time of discontinuing from the study, if possible, an early discontinuation/final
visit should be conducted, as shown in the SoA. See SoA for data to be collected at the 
time of study discontinuation and follow-up and for any further evaluations that need 
to be completed.

The participant will be permanently discontinued both from the study intervention and 
from the study at that time.

If the participant withdraws consent for disclosure of future information, the sponsor 
may retain and continue to use any data collected before such a withdrawal of consent.

A participant must be withdrawn from the study if the development of an inhibitory 
antibody to Jivi that neutralizes activity sufficiently to interfere with effective 
treatment or requires use of a bypassing agent to treat bleeds.

A participant must be withdrawn from the study if he fails to comply with scheduled 
appointments for the study-related evaluations and with EPD data entry to an extent 
that compromises collection of critical data.

A participant must be withdrawn from the study if significant concurrent illness or 
deterioration occurs in the participant’s condition, including laboratory values that the 
investigator deems to be incompatible with the participant’s continued safe 
participation in the study.


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  25 of 54
7.3
Lost to Follow Up
A participant will be considered lost to follow-up if he repeatedly fails to return for scheduled 
visits and is unable to be contacted by the study site. 
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit:

The site must attempt to contact the participant and reschedule the missed visit as soon 
as possible and counsel the participant on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the participant wishes to and/or should 
continue in the study.

Before a participant is deemed lost to follow up, the investigator or designee must 
make every effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary, a letter to the participant’s last known mailing address or local 
equivalent methods). These contact attempts should be documented in the participant’s 
medical record.

Should the participant continue to be unreachable, he will be considered lost to follow 
up.
8.
Study Assessments and Procedures

Study procedures and their timing are summarized in the SoA and visit description 
Section 10.4.  Protocol waivers or exemptions are not allowed.

Immediate safety concerns should be discussed with the sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
study intervention.

Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.

All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. 

Procedures conducted as part of the participant’s routine clinical management (e.g., 
blood count) and obtained before signing of the ICF may be utilized for screening or 
baseline purposes provided the procedures met the protocol-specified criteria and were 
performed within the time frame defined in the SoA.

If deemed necessary for an individual participant, the investigator or designee, at 
his/her discretion, may arrange visits in addition to the scheduled study visits.  
Unscheduled visits will be documented in the eCRF.


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  26 of 54
8.1
Efficacy Assessments 
This is a post authorization safety study (PASS). The efficacy endpoints are secondary 
endpoints for the study and include:
Secondary Endpoints throughout the study

ABR 
Other exploratory endpoints pre-specified throughout the study

Percentage of participant with 0 spontaneous bleeds during a 6-month treatment

Total number of exposures

Consumption: dose/kg per participant/year 

Type, location and severity of bleeds, reason for each injection, and response to 
treatment of bleeds
Further endpoints are specified in the SAP.
8.1.1
Treatment Logs/Bleeding Verification
Treatment logs are commonly used for hemophilia participants for documentation of their 
home treatment. Home treatment and bleeding information are the key variables for 
evaluation of efficacy. Study specific treatment logs will be provided in national language. 
The system for this study will be electronic patient diary (EPD) devices since they are 
interactive, allow for real time data transmission, record-stamp date and time of fulfillment 
and facilitate the clarification of data with the site and also the data cleaning process. 
Participants will be provided with EPDs for the whole study. At Screening visit, participants
will be trained in the use of the device. These logs will be used to collect the treatment data 
and bleeding episodes by the participants, and the data will be verified for accuracy and 
completion by the investigator or delegate during regularly scheduled interactions with the 
participant. Thus, the EPD will be considered the source for these data.
For each self-administered injection of Jivi, information must be recorded on the EPD as 
follows:
Each injection of Jivi: 
a.
Date and time
b. Injection record
c.
Individual vial number (bar code scan from vial label or manual entry) and units 
administered
d. Reason for treatment
Prophylaxis
Spontaneous bleed first treatment
Trauma bleed first treatment
Follow-up treatment
Other


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  27 of 54
Injections of Jivi as part of protocol mandated visits and procedures will be recorded on the 
respective CRF pages.
All bleeding episodes (regardless if treated or not, or treated at home or under medical 
supervision) as well as any potential treatment with other hemophilia drugs will be recorded 
in the EPD:
Bleeding episode (onset)
a.
Date and time of onset
b. Type of bleed (spontaneous, trauma; joint, muscle, skin/mucosal, internal, other)
c.
Location
d. Intensity (mild, moderate, severe)
e.
Treated [yes/no]; 
if “yes”:
Date and time
Product used: Jivi or other
Doses
If Jivi is used for the treatment of a bleeding episode, the response to treatment (excellent, 
good, moderate, poor, too early to tell) must to be recorded
For guidance to the participant, the following definitions for response to treatment are 
suggested:
Excellent: Abrupt pain relief and/or improvement in signs of bleeding with no additional 
injection administered 
Good: Definite pain relief and/or improvement in signs of bleeding, but possibly requiring 
more than one injection for complete resolution
Moderate: Probable or slight improvement, with at least one additional injection for complete 
resolution 
Poor (or None): No improvement or condition worsens.
8.1.2
Incremental Recovery of Jivi 
Blood samples for Jivi trough (predose) and recovery levels (15-30 min post injection) will be 
collected in all participants. Incremental recovery will be determined by collecting a sample 
for FVIII level before the scheduled injection, and a second sample collected 15-30 min after 
end of the injection. The exact sampling times before and after injection and the dose 
administered will be documented in the CRF. Incremental recovery of Jivi is determined by 
measuring FVIII activity.
Injections given at study visits will be recorded in the site participant records, which will be 
the source documents and will be used to enter this information in the CRF. 
The samples will be collected as described in detail in the laboratory manual. All samples will 
be processed in the central laboratory. Plasma concentrations of FVIII will be measured using 
a validated FVIII activity assay (“chromogenic assay”).


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  28 of 54
Samples for incremental recovery should be collected on days when the next prophylactic 
injection is scheduled and at least 72 h after the prior injection has been given. The 
measurements should only be performed when the participant is not actively bleeding.
Recoveries should be performed using the participants assigned treatment dose, rounded to 
full vial size. 
Samples will be collected at Baseline, Visit 3 (Week 8-10), and Last Visit, or in case of 
suspicion of loss of efficacy (LoE)/hypersensitivity and at additional time points based on the 
investigator’s discretion.
8.1.3
Activity Tracker
 
 
 
 
 
 
 
8.2
Safety Assessments 
Planned time points for all safety assessments are provided in the SoA.
The safety endpoints for the study include:
Primary Endpoints throughout the study: 
!
FVIII inhibitor development by the Nijmegen Bethesda assay. Any positive inhibitor 
test will be confirmed by testing a second separately drawn sample in a central 
laboratory
Secondary Endpoints throughout the study:
!
TEAE.
!
Treatment-emergent anti-drug antibodies (ADA) against Jivi and Anti-PEG antibodies 
at the same time points as the FVIII inhibitor tests and in case of clinical suspicion of 
LoE/Hypersensitivity
8.2.1
Measurements of Immunogenicity
All participants will be tested for immunogenicity at Screening, Baseline (Day 1), Visit 3, 
Visit 4, Visit 5, and Last Visit, or in case of suspicion of LoE/hypersensitivity.
CCI
CCI


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  29 of 54
Antibodies to Jivi and/or PEG (ADA)
Binding antibodies to Jivi and/or PEG are analyzed in an enzyme-linked immunosorbent 
assay (ELISA) Type screening ADA assay using Jivi. Positive screened samples will be 
characterized for specificity of the antibody response against Jivi and/or against PEG and for 
their neutralizing activity.
FVIII inhibitor
FVIII inhibitor testing will be done according to the Nijmegen modified Bethesda assay. A 
positive inhibitor test is defined with a threshold of ≥0.6 BU at the central laboratory.
If an inhibitor is detected as part of scheduled testing, the investigator will to be notified. 
Repeat testing within 2 to 4 weeks of notification should to be obtained. Any positive test will 
be confirmed by a second different sample. Only after confirmation of the positive result, the 
inhibitor has to be reported as SAE.
Loss of Efficacy (LoE)/Hypersensitivity reaction
In case loss of efficacy is suspected by the investigator (ie, measured by low FVIII levels, 
poor recovery, and unexpected clinical symptoms of bleeding or no response to treatment of a 
bleed) or the participant presents symptoms of an hypersensitivity reaction, plasma samples 
will be tested for FVIII inhibitor and ADA, and positive screened samples will be further 
characterized for specificity of the antibody response against Jivi and/or against PEG. 
Samples that confirmed positive against Jivi will be further analyzed in a modified Nijmegen 
Bethesda assay for inhibitory activity against Jivi.
In addition to this, incremental recovery following administration of Jivi will be measured. 
Samples for Jivi trough and recovery levels following an injection of Jivi will be collected 
when loss of efficacy is suspected (See Section 8.1.2). In case of a slightly reduced recovery 
(compared to previous product or below 1.5 IU/dl per IU/kg), the recovery should be repeated 
locally after the next injection.
A clinical immune response manifested as symptoms of acute hypersensitivity and/or loss of 
drug effect has been observed primarily in children < 6 years, within the first 4 exposure days,
which was associated with anti-PEG antibodies.
 
 in such cases Jivi should be discontinued, participants should 
switch to a previously effective factor VIII product, and the recovery should be measured 
locally after injection of the previous FVIII which will be normal in these cases, ruling out an 
inhibitor. 
8.2.2
Physical Examinations
!
Physical examinations will be performed at Screening and End of Study/Early 
Termination Visit. 
CCI


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  30 of 54

A complete physical examination will include, at a minimum, assessments of the 
general appearance, dermatologic, head, eyes, ears, nose, mouth/throat/neck, thyroid, 
lymph nodes, cardiovascular, respiratory, gastrointestinal extremities, neurological and 
musculoskeletal and review of systems.  Height and weight will also be measured and 
recorded.

Body weight will be measured every 6 months (Visits 4, 5, and 6).

Investigators should pay special attention to clinical signs related to previous serious 
illnesses.  Any abnormal finding should be documented.
8.2.3
Vital Signs

Vital signs will be measured at Screening, Baseline, and End of Study/Early 
Termination Visit.  In case of any in-hospital injection related AE, vital signs will be 
measured post-injection for participants.

Heart rate, respiratory rate, and systolic and diastolic blood pressure will be assessed.

Blood pressure and heart rate measurements should be preceded by at least 5 minutes 
of rest for the participant in a supine or seated position without distractions (e.g., 
television, cell phones).
8.2.4
Clinical Safety Laboratory Assessments

See Section 10.2 for the list of clinical laboratory tests to be performed and to the SoA 
for the timing and frequency. 

The investigator must review the laboratory report, document this review, and record 
any clinically relevant changes occurring during the study in the AE section of the 
CRF. The laboratory reports must be filed with the source documents. Clinically 
significant abnormal laboratory findings are those which are not associated with the 
underlying disease, unless judged by the investigator to be more severe than expected 
for the participant's condition.

All laboratory tests with values considered clinically significantly abnormal during 
participation in the study should be repeated until the values return to normal or 
baseline or are no longer considered clinically significant by the investigator.
o
If such values do not return to normal/baseline within a period of time 
judged reasonable by the investigator, the etiology should be identified and 
the sponsor notified.
o
All protocol-required laboratory assessments, as defined in Section 10.2, 
must be conducted in accordance with the laboratory manual and the SoA. 
o
If laboratory values from non-protocol specified laboratory assessments 
performed at the institution’s local laboratory require a change in 
participant management or are considered clinically significant by the 
investigator (e.g., SAE or AE or dose modification), then the results must 
be recorded in the CRF. 


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  31 of 54
8.3
Adverse Events and Serious Adverse Events
The definitions of an AE or SAE can be found in Section 10.3.
AE will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the 
participant's legally authorized representative or health care professional not involved in the 
study).
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE. They remain responsible for 
following up SAEs, or AEs considered related to the study intervention or study procedures, 
or those that caused the participant to discontinue the study. Events of Special Interest have to 
be followed up regardless of causality or relationship to study intervention (see Section 8.3.7).
8.3.1
Time Period and Frequency for Collecting AE and SAE Information 
All AEs and SAEs will be collected from the signing of the informed consent form (ICF) until 
the end of the final study visit at the time points specified in the SoA (Section 1.3).
Medical occurrences that begin before obtaining informed consent but are diagnosed at 
screening or during the screening period (e.g., abnormal lab values) will be recorded on the 
Medical History/Current Medical Conditions section of the case report form (CRF), not the 
AE section.
All SAEs will be recorded and reported to the sponsor or designee immediately and under no 
circumstances should this exceed 24 hours, as indicated in Section 10.3. The investigator will 
submit any updated SAE data to the sponsor within 24 hours of it being available.
Investigators are not obligated to actively seek AE or SAE after conclusion of the study 
participation. However, if the investigator learns of any SAE, including a death, at any time 
after a participant has been discharged from the study, and he considers the event to be 
reasonably related to the study intervention or study participation, the investigator must 
promptly notify the sponsor. 
8.3.2
Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality of AE and SAE and the 
procedures for completing and transmitting SAE reports are provided in Section 10.3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about AE 
occurrences. 
8.3.3
Follow-up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs and non-serious AEs of special interest (as 
defined in Section 8.3.7, will be followed until resolution, stabilization, the event is otherwise 
explained, or the participant is lost to follow-up (as defined in Section 7.3). Further 
information on follow-up procedures is given in Section 10.3.3. 


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  32 of 54
8.3.4
Regulatory Reporting Requirements for SAEs

Prompt notification by the investigator to the sponsor of an SAE is essential so that 
legal obligations and ethical responsibilities towards the safety of participants and the 
safety of a study intervention under clinical investigation are met. 

The sponsor has a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies about the safety of a study intervention under clinical 
investigation.  The sponsor will comply with country-specific regulatory requirements 
relating to safety reporting to the regulatory authority, Institutional Review Boards 
(IRB)/Independent Ethics Committees (IEC), and investigators.

Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (SUSAR) according to local regulatory requirements and sponsor policy and 
forwarded to investigators as necessary.

An investigator who receives an investigator safety report describing an SAE or other 
specific safety information (e.g., summary or listing of SAEs) from the sponsor will 
review and then file it along with the Investigator’s Brochure and will notify the 
IRB/IEC, if appropriate according to local requirements.
8.3.5
Pregnancy
Contraception Guidance

It has been shown that there is no target-related specific transport mechanism for Jivi 
into semen or from semen into the conceptus.  Following administration to a male 
participant, Jivi would not be bioavailable via seminal delivery to the developing
conceptus of an untreated partner.  Therefore, no method of contraception is needed.
Collection of Pregnancy Information

Bayer usually does not gather pregnancy information of drug exposure via father; 
however, if those cases are reported, details of all pregnancies in female partners of 
male participants will be collected after the start of study intervention and until one 
week period that is at least 5 terminal half-lives after the last dose.

If a pregnancy is reported, the investigator should inform the sponsor of learning of 
the pregnancy.
8.3.6
Disease-Related Events and/or Disease-Related Outcomes Not 
Qualifying as AEs or SAEs
The following disease related outcome is common in participants with hemophilia A and can 
be serious/life threatening:

Bleeding event
Any bleeding event, regardless if treated or not, occurring during the study will not be 
documented as an AE, because this is captured in the assessment of efficacy.


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  33 of 54
Because these events are typically associated with the disease under study, they will not be 
reported according to the standard process for expedited reporting of AEs. These events will 
be recorded in the EPD.
NOTE: However, if the bleed fulfills the criterion for an SAE (e.g. results in hospitalization), 
then the event should be recorded and reported as an SAE (see Section 10.3.2).
8.3.7
Events of Special Interest
Hypersensitivity reactions are a known and listed adverse drug reactions for FVIII products 
and have been reported with use of Jivi. Loss of efficacy of the drug product has also been 
reported in children < 6 years of age and may be associated with the development of 
antibodies to PEG. All such reported events occurred early in treatment, within the first 4 ED.  
Both of these events are defined in this study as adverse events of special interest and must be 
reported as adverse events.
In the event of such a hypersensitivity reaction or reported loss of efficacy of the treatment 
product, antibody and inhibitor testing will be obtained.  Loss of efficacy needs to be 
documented by pre and post factor VIII levels around an injection of the Jivi, using 
appropriate laboratory measures, and be confirmed in the central laboratory.
 
 
8.4
Treatment of Overdose
Sponsor does not recommend specific treatment for an overdose.
8.5
Pharmacokinetics
PK parameters are not evaluated in this study.
8.6
Pharmacodynamics
Pharmacodynamic parameters are not evaluated in this study.
8.7
Genetics
Genetics parameters are not evaluated in this study.
8.8
Biomarkers
Biomarkers for renal safety will be evaluated in the study (see Section 10.2 Appendix 2).
CCI


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  34 of 54
8.9
Other investigations
 
 
 
8.10
Health Economics OR Medical Resource Utilization and Health 
Economics 
Health Economics/Medical Resource Utilization and Health Economics parameters are not 
evaluated in this study. 
9.
Statistical Considerations 
9.1
Statistical Hypotheses
The study is not designed to test any predefined hypothesis. All analyses will be descriptive or 
exploratory.
9.2
Sample Size Determination 
Descriptive statistics will be used. The sample size is defined by the Note for guidance on the
clinical investigation of recombinant FVIII products in order to fulfill post-marketing 
requirements. During the clinical development program, a total of 232 participants were 
included in the Phase 1 and 2/3 clinical development program. Among these participants, 168 
participants achieved >100 ED, and additional 17 participants achieved 50-100 ED. It is 
considered, that at least additional 25 participants would support the assessment of general 
safety and efficacy as required by guidelines EMA/CHMP/BPWP/144533/2009 rev.2 (EMA 
2017).
A pooled analysis will be performed for all patients included in the Phase III and IV studies. 
The following trials will be included in the pooled analysis:
Study
Total number of participants included
PROTECT VIII
134
PROTECT Kids
73
Planned Phase IV study
≥25
Expected total
≥232
Assessment of safety will be done for the safety population including all participants with at 
least 1 injection of Jivi. Assessment of efficacy will be performed for the ITT population 
including participants with diary/injection data available.
CCI
CCI
CCI


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  35 of 54
9.3
Populations for Analyses 
For purposes of analysis, the following populations are defined:
Population
Description
Enrolled
All participants who sign the ICF
Safety population for the study 
19764
Participants enrolled into the study and received at least 1 dose 
of study intervention.  Participants will be analyzed according to 
the intervention they actually received.
The safety population will be used for the safety analysis.
Intent-to-treat (ITT) population for 
the study 19764
All safety participants who have injection/bleeding data from 
the EPD and CRF for at least 3 months.
The ITT population will be used for the efficacy analysis.
Safety population for pooled 
analysis
The safety population for the pooled analysis will consist of the 
safety population of this study as defined above and the safety 
populations of studies 13024 Part A and 15912.
Efficacy population for pooled 
analysis
The efficacy population for the pooled analysis will consist of 
the ITT population of this study as defined above and the 
extension ITT populations of studies 13024 Part A and 15912.
9.4
Statistical Analyses
The statistical analysis plan will be developed and finalized before first patient first visit 
(FPFV) and will describe the participant populations to be included in the analyses, and 
procedures for accounting for missing, unused, and spurious data. This section is a summary 
of the planned statistical analyses of the primary and secondary endpoints.
9.4.1
Efficacy Analyses
The secondary objective of the study is to assess clinical efficacy. All efficacy analyses will 
be performed on the ITT population with a treatment period of at least 3 months.
The following efficacy variables will be analyzed:

Annualized bleeding rate for joint and spontaneous bleeds

Percentage of participants with 0 spontaneous bleeds within a 6-months treatment 
period 

Annualized number of total bleeds (sum of spontaneous bleeds and trauma bleeds)

Incremental recovery will be summarized

Total number of exposure per year will be documented in patient diaries and 
summarized

Extent of exposure to study intervention during the study in terms of exposure days 
(ED) and injection characteristics (number of units, consumption dose/kg per 
participant/year, reason for treatment, type, location and severity of bleeds and 
response to treatment) will be summarized for each participant receiving any amount 
of drug.


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  36 of 54
Other pre-specified exploratory endpoints will be described in the statistical analysis plan 
finalized before database lock.
An integrated efficacy analysis will be done based on combined data from this study and 
studies 13024 Part A and 15912. Results will be provided by age groups.
9.4.2
Safety Analyses
All safety analyses will be performed on the Safety Population. Laboratory findings, adverse 
events, concomitant medications, vital signs, and medical history data will be provided in 
subject listings.
Those participants who were given at least one dose of Jivi will be valid for the safety 
analysis. Inhibitor development will be summarized by time point and presented in subject 
listings. The purpose of the listing is to delineate the clinical factors which may be positively 
associated with development of the inhibitor. Confirmation of positive inhibitor titers 
(Bethesda ≥0.6 BU/mL) will require repeat measurement. If the repeated inhibitor result is
<0.6 BU without intervention, the inhibitor is not confirmed and should not be reported as an
SAE. Inhibitors will be classified as being either low titer (≥0.6 BU/mL and ≤5 BU/mL) or 
high titer based upon persistence of an inhibitor >5 BU. Participants will also be monitored
for other antibodies against the drug substance Jivi and/or PEG. Proportions of participants 
with inhibitor or antibodies will be presented in an overview table.
Laboratory values and vital signs will be summarized. Individual listings of AEs (including 
AEs as reported, start, duration, severity, relation to study drug) will be provided. The 
incidence of treatment-emergent adverse events (AEs) will be summarized using the Medical 
Dictionary for Regulatory Activities (MedDRA). An AE will be considered treatment-
emergent if it starts after first injection and not later than 7 days after last injection of Jivi.
Integrated safety analyses will be done based on combined data from this study and studies 
13024 Part A and 15912. Summary tables for demographics, baseline characteristics
(including gene defect), medical history (including family history of hemophilia and history 
of inhibitor), concomitant medications, extent of exposure, treatment-emergent AEs, and 
laboratory findings will be provided. Results will be provided by age groups.
9.5
Interim Analyses 
An optional interim analysis will be performed, if needed for regulatory submission or 
publication purposes, after all participants have been treated for 6 months for assessment of 
the main safety (inhibitor development) and efficacy endpoints. The risk for inhibitor 
development is highest during the first 20-50 ED. After this timepoint, the study would be 
continued according to the study design and protocol.


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  37 of 54
10.
Supporting Documentation and Operational Considerations
10.1
Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1
Regulatory and Ethical Considerations

This study is a post-approval regulatory requirement according to the EMA Guidelines 
for a new marketed FVIII and will be conducted in accordance with the protocol and 
with the following:

Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines

Applicable International Council for Harmonization (ICH) Good Clinical 
Practice (GCP) Guidelines

Applicable laws and regulations

The protocol, protocol amendments, ICF, SmPC, and other relevant documents (e.g., 
advertisements) must be submitted to an IRB/IEC by the investigator and reviewed 
and approved by the IRB/IEC before the study is initiated. 

Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes necessary to 
eliminate an immediate hazard to study participants. 

The investigator will be responsible for the following:

Providing written summaries of the status of the study to the IRB/IEC annually 
or more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/IEC

Notifying the IRB/IEC of SAEs or other significant safety findings as required 
by IRB/IEC procedures

Providing oversight of the conduct of the study at the site and adherence to 
requirements of ICH guidelines, the IRB/IEC, and all other applicable local 
regulations
10.1.2
Financial Disclosure
Investigators and sub-investigators directly involved in the treatment or evaluation of study
participants will provide the sponsor with sufficient, accurate financial information as 
requested to allow the sponsor to submit complete and accurate financial certification or 
disclosure statements to the appropriate regulatory authorities. Investigators are responsible 
for providing information on financial interests during the course of the study and for 1 year 
after completion of the study.


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  38 of 54
10.1.3
Informed Consent Process

The investigator and/or delegate will explain the nature of the study to the participant 
and answer all questions regarding the study, based on the patient informed consent.  
The patient informed consent will contain all relevant information on the study. 

Participants must be informed that their participation is voluntary.  Participants will be 
required to sign a statement of informed consent that meets the requirements of local 
regulations, ICH guidelines, where applicable, and the IRB/IEC or study center. 

The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study and the date the written 
consent was obtained.  The authorized person obtaining the informed consent must 
also sign the ICF.

Participants must be re-consented to the most current version of the ICF(s) during 
their participation in the study. 

A copy of the ICF(s) must be provided to the participant. 
Participants who are rescreened are required to sign a new ICF.
10.1.4
Data Protection

Participants will be assigned a unique identifier by the sponsor.  Any participant 
records or datasets that are transferred to the sponsor will contain the identifier only; 
participant names or any information which would make the participant identifiable 
will not be transferred. 

The participant must be informed that his personal study-related data will be used by 
the sponsor in accordance with local data protection law.  The level of disclosure must 
also be explained to the participant. 

The participant must be informed that his/her medical records may be examined by 
Clinical Quality Assurance auditors or other authorized personnel appointed by the 
sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory 
authorities.
10.1.5
Dissemination of Clinical Study Data
Result Summaries of Bayer's sponsored clinical trials in drug development phases II, III and 
IV and Phase I studies in patients are provided in the Bayer Trial Finder application after 
marketing authorization approval in line with the position of the global pharmaceutical 
industry associations laid down in the "Joint Position on the Disclosure of Clinical Trial 
Information via Clinical Trial Registries and Databases". In addition results of clinical drug 
trials will be provided on the publicly funded website www.ClinicalTrials.gov and EU 
Clinical Trials Register in line with the applicable regulations.
Bayer commits to sharing upon request from qualified scientific and medical researchers 
patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials 


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  39 of 54
in patients for medicines and indications approved in the United States (US) and European 
Union (EU) on or after January 01, 2014 as necessary for conducting legitimate research. 
All Bayer-sponsored clinical trials are considered for publication in the scientific literature 
irrespective of whether the results of the clinical trials are positive or negative.
10.1.6
Data Quality Assurance

All participant data relating to the study will be recorded on electronic CRF unless 
transmitted to the sponsor or designee electronically (e.g., laboratory data).  The 
investigator is responsible for verifying that data entries are accurate and correct by 
physically or electronically signing the CRF. 

The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.

The investigator must permit study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents. 

Monitoring details describing strategy (e.g., risk-based initiatives in operations and 
quality such as Risk Management and Mitigation Strategies and Analytical Risk-
Based Monitoring), methods, responsibilities and requirements, including handling of 
noncompliance issues and monitoring techniques (central, remote, or on-site 
monitoring) are provided in the Monitoring Plan.

The sponsor or designee is responsible for the data management of this study 
including quality checking of the data. 

The sponsor assumes accountability for actions delegated to other individuals (e.g., 
Contract Research Organizations).

Study monitors will perform ongoing source data verification to confirm that data 
entered into the CRF by authorized site personnel are accurate, complete, and 
verifiable from source documents; that the safety and rights of participants are being 
protected; and that the study is being conducted in accordance with the currently 
approved protocol and any other study agreements, ICH GCP, and all applicable 
regulatory requirements. 

Records and documents, including signed ICFs, pertaining to the conduct of this study 
must be retained by the investigator for 15 years after study completion unless local 
regulations or institutional policies require a longer retention period.  No records may 
be destroyed during the retention period without the written approval of the sponsor.  
No records may be transferred to another location or party without written notification 
to the sponsor. 


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  40 of 54
10.1.7
Source Documents

Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected.  Source documents are filed at the 
investigator’s site.

Data reported in the eCRF that are transcribed from source documents must be 
consistent with the source documents or the discrepancies must be explained.  The 
investigator may need to request previous medical records or transfer records, 
depending on the study.  Also, current medical records must be available.

Definition of what constitutes source data can be found in a source document 
checklist.

Patient reported outcome variables which are transmitted via EPD are considered 
source documentation.
10.1.8
Study and Site Closure
The sponsor designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study-site closure visit has been performed.
The investigator may initiate study-site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the early closure of a study site by the sponsor or investigator may include but are 
not limited to:

Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines

Inadequate recruitment of participants by the investigator

Discontinuation of further study intervention development
10.1.9
Publication Policy

The results of this study may be published or presented at scientific meetings.  If this 
is foreseen, the investigator agrees to submit all manuscripts or abstracts to the 
sponsor before submission.  This allows the sponsor to protect proprietary information 
and to provide comments. 

The sponsor will comply with the requirements for publication of study results.  In 
accordance with standard editorial and ethical practice, the sponsor will generally 
support publication of multicenter studies only in their entirety and not as individual 
site data.  In this case, a coordinating investigator will be designated by mutual 
agreement.

Authorship will be determined by mutual agreement and in line with International 
Committee of Medical Journal Editors authorship requirements.


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  41 of 54
10.2
Appendix 2: Clinical Laboratory Tests

The tests detailed in Table 10–1 will be performed by the central laboratory

All laboratory analyses will be performed at central laboratories.  Investigators will be 
provided with a laboratory manual for instructions on how to collect and process 
samples.

Protocol-specific requirements for inclusion or exclusion of participants are detailed in 
Section 5 of the protocol.

Additional tests may be performed at any time during the study as determined 
necessary by the investigator or required by local regulations locally or centrally as 
needed.
Table 10–1: Protocol-Required Safety Laboratory Assessments
Laboratory 
Assessments
Parameters
Hematology
Platelet Count
White blood cell (WBC) count with Differential
Erythrocytes
Hemoglobin
Hematocrit
Clinical 
Chemistry
Blood urea nitrogen 
(BUN)
Potassium
Aspartate 
Aminotransferase (AST)
Total bilirubin
Creatinine
Sodium
Alanine Aminotransferase 
(ALT)
Total Protein
Albumin
Routine 
Urinalysis

pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, leukocyte 
esterase by dipstick 
Renal 
Biomarkers

The urine samples for assessment of renal safety in participants with long 
term polyethylene glycol (PEG) exposure will include biomarkers (e.g. total 
protein and albumin [as albumin/creatinine ratio], and potentially 
beta-2microglobulin and Kim-1)
Other 
Laboratory 
Tests

Serology: HIV antibody for screening purpose only

Immunogenicity testing including antibodies to Jivi and/or PEG and FVIII 
inhibitor.

FVIII level

PEG level in plasma
All routine study-required laboratory assessments will be performed by a central 
laboratory, with the exception of some samples sent by central lab to 
independent specialty labs for required tests of FVIII level, FVIII inhibitors, 
antibodies to Jivi and/or PEG (anti-drug antibodies [ADA]) and PEG
Investigators must document their review of each laboratory safety report.


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  42 of 54
10.3
Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting
10.3.1
Definition of AE 
AE Definition
In a clinical study, an AE is any untoward medical occurrence (ie, any unfavorable and 
unintended sign [including abnormal laboratory findings], symptom or disease) in a 
subject or clinical investigation subject after providing written informed consent for 
participation in the study.  Therefore, an AE may or may not be temporally or causally 
associated with the use of a medicinal (investigational) product.
A surgical procedure that was planned prior to the start of the study by any physician 
treating the subject should not be recorded as AE (however, the condition for which the 
surgery is required may be an AE).
In the following differentiation between medical history and AEs, the term “condition” 
may include abnormal, eg, physical examination findings, symptoms, diseases, laboratory 
values.

Conditions that started before signing of informed consent and for which no 
symptoms or treatment are present until signing of informed consent are recorded 
as medical history (eg, seasonal allergy without acute complaints, abnormal 
laboratory finding at screening).

Conditions that started before signing of informed consent and for which 
symptoms or treatment are present after signing of informed consent, at unchanged 
intensity, are recorded as medical history (eg, allergic pollinosis).

Conditions that started or deteriorated after signing of informed consent will be 
documented as adverse events.
Note:  Any bleeding event occurring during the study will not be documented as an AE, 
because this event is captured in the assessment of efficacy.  However, if the bleed 
requires hospitalization or fulfills another seriousness criterion, it must be reported as a 
Serious Adverse Event (SAE) (Section 10.3.2).
Bleeding events treated with Jivi and recorded in the EPD do not need to be documented 
as AEs because they are already captured.  However, occurrence of traumatic injury and 
other bleeds should follow standard AE reporting procedures.  Any bleed requiring 
hospitalization or fulfilling another seriousness criterion must be reported as a SAE 
(Section 10.3.2).


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  43 of 54
Events Meeting the AE Definition 

Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition.

New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.

Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.

Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication.  Overdose per se will not be reported as 
an AE/SAE unless it is an intentional overdose taken with possible suicidal/self-
harming intent.  Such overdoses should be reported regardless of sequelae.

The signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be 
reported as AE or SAE if they fulfil the definition of an AE or SAE.  Also, “lack of 
efficacy” or “failure of expected pharmacological action” also constitutes an AE or 
SAE.  
Events NOT Meeting the AE Definition 

Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condition.

The disease/disorder being studied or expected progression, signs, or symptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.

Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that 
leads to the procedure is the AE.

Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).

Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen. 

Any bleeding event occurring during the study will not be documented as an AE, 
because this is captured in the assessment of efficacy.  However, if the bleed fulfills 
the criterion for an SAE (e.g. results in hospitalization), then the event should be 
recorded and reported as an SAE.


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  44 of 54
10.3.2
Definition of SAE
An SAE is defined as any untoward medical occurrence that, at any dose:
a.
Results in death
b.
Is life-threatening

The term 'life-threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event.  It does not refer to an event, 
which hypothetically might have caused death, if it were more severe.
c.
Requires inpatient hospitalization or prolongation of existing hospitalization
A hospitalization or prolongation of hospitalization will not be regarded as an SAE 
if at least one of the following exceptions is met:
o
The admission results in a hospital stay of less than 12 hours
o
The admission is pre-planned 
(ie, elective or scheduled surgery arranged prior to the start of the study)
o
The admission is not associated with an AE 
(eg, social hospitalization for purposes of respite care).
However, it should be noted that invasive treatment during any hospitalization may 
fulfill the criterion of ‘medically important’ and as such may be reportable as an 
SAE dependent on clinical judgment.  In addition, where local regulatory authorities 
specifically require a more stringent definition, the local regulation takes 
precedence.
d.
Results in persistent disability/incapacity

The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.

This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (e.g., sprained ankle) which may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption.
e.
Is a congenital anomaly/birth defect
f.
Is another medically important serious event as judged by the investigator.

Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediately life-threatening or result in death or hospitalization but may 
jeopardize the participant or may require medical or surgical intervention to prevent 
one of the other outcomes listed in the above definition.  These events should 
usually be considered serious.

Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalization, or development of drug dependency 
or drug abuse.


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  45 of 54
10.3.3
Recording and Follow-Up of AE and/or SAE 
AE and SAE Recording

When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g., hospital progress notes, laboratory reports, and diagnostics 
reports) related to the event.

The investigator will then record all relevant AE/SAE information in the CRF.

It is not acceptable for the investigator to send photocopies of the participant’s 
medical records to Study Monitor/Medical Monitor in lieu of completion of the 
AE/SAE CRF page.

There may be instances when copies of medical records for certain cases are 
requested by the Sponsor.  In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copies of the medical 
records before submission to the Sponsor.

The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  Whenever possible, the diagnosis 
(not the individual signs/symptoms) will be documented as the AE/SAE.
Assessment of Intensity

The investigator will make an assessment of intensity for each AE and SAE 
reported during the study and assign it to 1 of the following categories: 

Mild: An event that is easily tolerated by the participant, causing minimal 
discomfort and not interfering with everyday activities.

Moderate: An event that causes sufficient discomfort and interferes with normal 
everyday activities.

Severe: An event that prevents normal everyday activities.  An AE that is assessed 
as severe should not be confused with an SAE.  Severe is a category utilized for 
rating the intensity of an event; and both AEs and SAEs can be assessed as severe.

An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality

The investigator is obligated to assess the relationship between study intervention 
and each occurrence of each AE/SAE.

A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.

The investigator will use clinical judgment to determine the relationship.

Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study intervention 
administration will be considered and investigated.


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  46 of 54

The investigator will also consult the Investigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.

For each AE/SAE, the investigator must document in the medical notes that he has 
reviewed the AE/SAE and has provided an assessment of causality.

There may be situations in which an SAE has occurred, and the investigator has 
minimal information to include in the initial report to the Sponsor.  However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the Sponsor.

The investigator may change his/her opinion of causality in light of follow-up 
information and send an SAE follow-up report with the updated causality 
assessment.

The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.
Follow-up of AEs and SAEs

The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by the 
Sponsor to elucidate the nature and/or causality of the AE or SAE as fully as 
possible.  This may include additional laboratory tests or investigations, 
histopathological examinations, or consultation with other health care 
professionals.

New or updated information will be recorded in the originally completed CRF.

The investigator will submit any updated SAE data to the Sponsor within 24 hours 
of receipt of the information.
10.3.4
Reporting of SAEs
SAE Reporting to the Sponsor via an Electronic Data Collection Tool

The primary mechanism for reporting an SAE will be the electronic data collection 
tool.

If the electronic system is unavailable, then the site will use the paper SAE data 
transmission (see next section) in order to report the event within 24 hours.

The site will enter the SAE data into the electronic system as soon as it becomes 
available.

After the study is completed at a given site, the electronic data collection tool will be 
taken off-line to prevent the entry of new data or changes to existing data.

If a site receives a report of a new SAE from a study participant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off-line, then the site can report this information on a paper SAE form (see 
next section) or to the Sponsor’s Medical Monitor by telephone.

Contacts for SAE reporting can be found in the investigator Site File.


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  47 of 54
SAE Reporting to the Sponsor via Paper CRF

Email transmission of the SAE paper CRF is the preferred method to transmit this 
information to the Sponsor´s Medical Monitor.

In rare circumstances and if email transmission is not feasible, notification by 
telephone is acceptable with a copy of the SAE data collection tool sent by overnight 
mail or courier service.

Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.

Contacts for SAE reporting can be found in the investigator Site File.
10.4
Appendix 4: Visit Description
10.4.1
Visit 1 – Screening (Approximately 2 to 8 Weeks)
Screening may take place over multiple site visits. At the Screening Visit, the following 
procedures and assessments will be performed:

Obtain signed informed consent from participants
Note: No screening procedures should be performed unless written informed consent 
has been obtained

Allocation of a unique participant number

Review of eligibility requirements; no participant should receive study intervention 
unless all inclusion and exclusion criteria are met listed in Section 5.1 and 5.2. 
Confirmation of selection criteria may be based on medical records for some 
conditions, but laboratory test results must be available for the listed items to confirm 
eligibility. 

Collect demographic data (age, sex [male only], race, ethnicity, and gene defect)

Full physical examination including neurological standard assessment, height, and 
weight

Collect information on activity level (type of sports, hrs/wk)

Obtain a complete medical and surgical history (general, disease, family history of 
hemophilia, and history of inhibitor development)
o
Include any information on cardiovascular risk, hepatic disease, renal impairment, 
prior use of PEGylated medications (e.g., PEG- interferon, PEG-anti- tumor 
necrosis factor [TNF])
o
Specific information on history of hemophilia (date of diagnosis, start of therapy, 
prior and current factor VIII products, number of ED, type of factor VIII gene 


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  48 of 54
mutation (from history), family history, FVIII level, family and personal history 
of past inhibitor formation, current treatment product and regimen, number and 
type of bleeds in the last 12 months, and presence and location of target joints.)  If 
available, data on prior PK with the participants’ previous FVIII product will be 
collected (e.g. recovery and half-life).

Collect information on previous medication (medication history)

Vital signs (Heart rate, respiratory rate, and blood pressure; see Section 8.2.3)

Urine sample (routine urinalysis and renal biomarkers; see Table 10–1)

Blood samples for (see details in Table 10–1):
o
Laboratory evaluation (hematology and clinical chemistry)
o
HIV screening (in case negative result in patient documentation is older than 1 
year at date of screening)
o
CD 4+ cell count (only if participant is HIV positive)
o
Immunogenicity testing
o
PEG level in plasma

Training on and dispense of EPD devices 

Training and dispense of activity tracker; ask the participant to wear activity tracker 
for continuous 2-3 weeks after screening before Baseline Visit (see Section 8.1.3)

Concomitant medication review

AE review
10.4.2
Visit 2 – Baseline Predose (Day 1)
This visit will be serving as the Baseline Visit; it will include the first administration of study 
intervention. The Baseline Visit should take place within 2 to 8 weeks after Screening Visit 
and at least 72 hour after last FVIII product administration.
This visit should start with the following assessments:

Confirmation of eligibility including check of laboratory test results
Note: Participants must have negative results from the central laboratory for inhibitory 
antibodies against FVIII (< 0.6 BU determined with the Nijmegen modified Bethesda 
assay)
Thereafter, the following procedures and assessments will be performed and data recorded:

Remind the participants to wear the activity tracker for 2-3 continuous weeks after the 
start of treatment before Visit 3

Concomitant medication review

AE review 

Vital signs (Heart rate, respiratory rate, and blood pressure; see Section 8.2.3)


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  49 of 54

Urine sample (routine urinalysis and renal biomarkers; see Table 10–1)

Blood sample collection before administration of study intervention
o
Blood samples for:
- Immunogenicity testing
- Incremental recovery of Jivi

In-hospital injection of Jivi

Procedures and sample collection after administration of study intervention
o
Blood samples for:
- Incremental recovery of Jivi (15-30 min after end of injection; see Section 
8.1.2) 
o
In case of any injection related AE at site, vital signs will be collected 

Dispense study intervention for home injections in accordance with IxRS drug 
dispensing schedule

Instruction on the treatment regimen to be administered to the participant

Check of EPD entries and bleeding history

Begin regular monthly contact between participant and the site to check EPD 
documentation and AE review until the End of Study/Early Termination
10.4.3
Visit 3 – ED 10-15 (Week 8-10)
This visit should take place at least 72 hours after the last injection of Jivi.

Dose regimen adjustment

Blood sample collection before administration of study intervention:
o
Immunogenicity testing 
o
Incremental recovery of Jivi

In-hospital injection of Jivi 

Procedures and blood sample collection after administration of study intervention
o
Incremental recovery of Jivi (15-30 min after end of injection; see Section 8.1.2) 
o
In case of any injection related AE at site, vital signs will be measured

Concomitant medication review

AE review

Check of EPD entries and bleeding history

Dispense study intervention for home injections in accordance with IxRS drug 
dispensing schedule


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  50 of 54

Return used and unused study intervention

Continue regular monthly contact between participant and the site to check EPD 
documentation and AE review until the End of Study/Early Termination
10.4.4
Visit 4 – ED 50-75 (Month 6 ± 14 days)
This visit should take place approximately 48 or 72 hours (if not possible then 96 hours) after 
the last injection of Jivi.

Ask the participant to wear activity tracker for continuous 2-3 weeks after Visit 4 
(Month 6) before Visit 5 (Month 12)

Body weight measurement

Concomitant medication review

AE review

Blood samples for (see details in Table 10–1): 
o
Immunogenicity testing
o
FVIII level

Dispense study intervention for home injections in accordance with IxRS drug 
dispensing schedule

Return used and unused study intervention

Check of EPD entries and bleeding history

Continue regular monthly contact between participant and the site to check EPD 
documentation and AE review until the End of Study/Early Termination
10.4.5
Visit 5 – ED 50-75 (Month 12 ± 14 days)
This visit should take place approximately 48 or 72 hours (if not possible then 96 hours) after 
the last injection of Jivi.

Body weight measurement

Concomitant medication review

AE review

Urine sample (routine urinalysis and renal biomarkers; see Table 10–1)

Blood samples for (see details in Table 10–1):
o
Laboratory evaluation (hematology and clinical chemistry)
o
Immunogenicity testing
o
FVIII level


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  51 of 54

Dispense study intervention for home injections in accordance with IxRS drug 
dispensing schedule

Return used and unused study intervention

Check of EPD entries and bleeding history

Documentation of activity tracker; return activity tracker

Continue regular monthly contact between participant and the site to check EPD 
documentation and AE review until the End of Study/Early Termination
10.4.6
Visit 6 if needed – ED 50-75 (Month 18 ± 14 days)

Body weight measurement

Concomitant medication review

AE review

Dispense study intervention for home injections in accordance with IxRS drug 
dispensing schedule

Return used and unused study intervention

Check of EPD entries and bleeding history

Continue regular monthly contact between participant and the site to check EPD 
documentation and AE review until the End of Study/Early Termination
10.4.7
Last Visit – ED 100 (End of Study/Early Termination + 14 days)
This visit should take place at least 72 hours after the previous injection of Jivi.
The following procedures and assessments will be performed in participants reach ED 100 or 
at the time of premature termination:

Concomitant medication review

AE review

Full physical examination including neurological standard assessment, height, and 
weight

Vital signs (Heart rate, respiratory rate, and blood pressure; see Section 8.2.3)

Urine sample (routine urinalysis and renal biomarkers; see Table 10–1)

Laboratory evaluation (hematology and clinical chemistry)

PEG level in plasma

Blood sample collection before administration of study intervention
o
Immunogenicity testing 


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  52 of 54
o
Incremental recovery of Jivi

In-hospital injection of Jivi

Procedures and blood sample collection after administration of study intervention
o
Incremental recovery of Jivi (15-30 min after end of injection; see Section 8.1.2) 
o
In case of any injection related AE at site, vital signs will be measured

Return used and unused study intervention

Check of EPD entries and bleeding history and return EPD 

Return activity tracker in case of early termination before Visit 5


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  53 of 54
10.5
Appendix 5: Abbreviations
ABR
Annualized bleeding rate
ADA
Anti-drug antibodies
AE
Adverse event
ALT
Alanine aminotransferase 
AST
Aspartate aminotransferase 
AUC
Area under the curve
BDD
B-domain deleted
BU
Bethesda unit
CD4
Cluster of differentiation 4 (CD4 receptor)
COX
Cyclooxygenase
CRF
Case Report Form (either paper or electronic)
ED
Exposure day
e.g.
exempli gratia, for example
EHL
Extended half-life
EMA
European Medicines Agency
EPD
Electronic patient diary
EU
European Union
FDA
US Food and Drug Administration
FVIII
Human coagulation factor VIII
GCP
Good Clinical Practice 
GMP
Good Manufacturing Practice
HIV
Human Immunodeficiency Virus
IB
Investigator’s Brochure
ICF
Informed consent form
ICH
International Council for Harmonization
ie
Id est, that is
IEC
Independent Ethics Committee
IMP
Investigational medicinal product
IRB
Institutional Review Board
ITT
Intent to treat
IU
International units
IV
Intravenous
IxRS
Interactive voice/web response system
Kg
Kilogram
LoE
Loss of efficacy
LPLV
Last participant last visit
MedDRA
Medical Dictionary for Regulatory Affairs
NIMP
Non investigational medicinal product
PEG
Polyethylene glycol
PK
Pharmacokinetic
PMDA
Pharmaceuticals and Medical Devices Agency
PMI
Post-marketing investigation


CONFIDENTIAL
Integrated Clinical Study Protocol
No. BAY 94-9027 / 19764
Version 2.0
Page:  54 of 54
PTP
Previously treated patients
QoL
Quality of Life
rFVIII
Recombinant factor VIII
SAP
Statistical analysis plan
SAE
Serious Adverse Event
SmPC
Summary of Product Characteristics
SoA
Schedule of activities
SUSAR
Suspected unexpected serious adverse reaction
t1/2
Half-life
TEAE
Treatment-emergent adverse event
WHO
World Health Organization
11.
References
Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes 
for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study 
Group. J Intern Med. 1994 Oct;236(4):391-9.
Coyle TE, Reding MT, Lin JC, Michaels LA, Shah A, Powell J. Phase I study of BAY 94-
9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-
life, in subjects with hemophilia A. J Thromb Haemost. 2014 Apr;12(4):488-96.
EMA. Guideline on the clinical investigation of recombinant and human plasma-derived 
factor VIII products. . 2017 Jan 28;EMA/CHMP/BPWP/144533/2009 rev 2. .
Ljung RC. Prophylactic treatment in Sweden--overtreatment or optimal model? Haemophilia. 
1998 Jul;4(4):409-12.
Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young 
patients--a long-term follow-up. J Intern Med. 1997 May;241(5):395-400.
Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. 
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe 
hemophilia. N Engl J Med. 2007 Aug 09;357(6):535-44.
Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of 
prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992 
Jul;232(1):25-32.
Petrini P, Lindvall N, Egberg N, Blomback M. Prophylaxis with factor concentrates in 
preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol. 1991 
Fall;13(3):280-7.
Reding MT, Ng HJ, Poulsen LH, Eyster ME, Pabinger I, Shin HJ, et al. Safety and efficacy of 
BAY 94-9027, a prolonged-half-life factor VIII. J Thromb Haemost. 2017 
Mar;15(3):411-9.

SAP_001.pdf: 
 
Document Type: 
Statistical Analysis Plan 
Official Title: 
Post-marketing investigation (PMI) to assess safety and efficacy of 
Jivi (BAY 94-9027) treatment in patients with hemophilia A 
NCT Number: 
NCT04085458 
Document Date: 
14-Mar-2022 
 


St atistic al A n al ysis Pl a n
B A Y 9 4- 9 0 2 7 / 1 9 7 6 4
Pa ge : 1 of 1 7
R ef er e n c e N u m b er: R D -S O P -1 1 1 9
S u p pl e m e nt V er si o n: 1 0
Ti tle p a ge
P ost -m ar keti n g i n vesti g ati o n ( P MI) t o assess s afet y a n d effic ac y of Ji vi 
( B A Y 9 4- 9 0 2 7) tre at me nt i n p atie nts wit h he m o p hili a A
Ji vi i nter ve nti o n al P MI st u d y t o assess s afet y a n d effic ac y
B a yer st u d y dr u g
B A Y 9 4 -9 0 2 7 / Da m oct oc o g alfa pe g ol; H u ma n Pe g y late d
r F VIII; Ji vi ®
St u d y p ur p ose:
P ost -mar keti n g re q uire me nts
Cli nic al st u d y 
p h ase:
I V
D ate:
1 4 M A R 2 0 2 2
St u d y N o.:
1 9 7 6 4
Versi o n:
2. 0 (a me n d me nt)
A ut h or:
 
C o nfi de nti al
T he i nf or mati o n pr o vi de d i n t his d oc u me nt is strictl y  c o nfi de ntial a n d is i nte n de d s olel y 
f or t he g ui da nce of t he cli nical i n vesti gati o n.  Re pr o d ucti o n or discl os ure of t his 
d oc u me nt, w het her i n part or i n f ull, t o parties n ot ass ociate d wit h t he cli nical 
i n vesti gati o n or its use f or a ny ot her p ur p ose wit h o ut t he pri or writte n c o nse nt of t he 
s p o ns or is n ot per mitte d.
T hr o u g h o ut t his d oc u me nt, s y m b ols i n dicati n g pr o prietar y na mes ( ®, T M) are n ot dis pla ye d.  H e nce, t he 
a p peara nce of pr o d uct na mes wit h o ut t hese s y m b ols d oes n ot i m pl y t hat t hese na mes are n ot pr otecte d.
T his Statistical A nal ysis Pla n is pr o d uce d o n a w or d -pr ocessi n g s yste m a n d bears n o si g nat ures.
T he a p pr o val of t he Statistical A nal ysis Pla n i s d oc u me nte d i n a se parate Si g nat ure D oc u me nt.
P P D
P P D


Statistical Analysis Plan
BAY 94-9027 / 19764
Page: 2 of 17
Reference Number: RD-SOP-1119
Supplement Version: 10
Table of Contents
Title page................................................................................................................................... 1
Abbreviations............................................................................................................................ 3
1.
Introduction....................................................................................................................... 4
2.
Study Objectives................................................................................................................ 4
3.
Study Design ...................................................................................................................... 5
4.
General Statistical Considerations .................................................................................. 6
4.1
General Principles............................................................................................................ 6
4.2
Handling of Dropouts ...................................................................................................... 7
4.3
Handling of Missing Data................................................................................................ 7
4.4
Interim Analyses and Data Monitoring ........................................................................... 8
4.5
Data Rules........................................................................................................................ 8
4.6
Blind Review/Validity review ....................................................................................... 11
5.
Analysis Sets .................................................................................................................... 11
5.1
Assignment of analysis sets ........................................................................................... 11
6.
Statistical Methodology .................................................................................................. 11
6.1
Population characteristics .............................................................................................. 11
6.2
Efficacy.......................................................................................................................... 12
6.3
Pharmacokinetics/pharmacodynamics........................................................................... 14
6.4
Safety ............................................................................................................................. 14
7.
Document history and changes in the planned statistical analysis............................. 16
8.
References ........................................................................................................................ 17
Table of tables
Table 2–1: Study objectives and endpoints for study 19764 ..................................................... 5
Table 3–1: Recommended dose regimen ................................................................................... 6


Statistical Analysis Plan
BAY 94-9027 / 19764
Page: 3 of 17
Reference Number: RD-SOP-1119
Supplement Version: 10
Abbreviations
ABR
Annualized bleeding rate
AE
Adverse event
ATC
Anatomical Therapeutic Chemical Classification
CRF
Case report form
DSMB
Data safety monitoring board
ED
Exposure Day
EE
Energy expenditure
EMA
European Medicines Agency
ePD
Electronic patient diary
FDA
Food and Drug Administration
ITT
Intent to treat set
IU
International Unit
IV
Intravenous
LLOQ
Lower limit of quantification
MedDRA
Medical Dictionary for Regulatory Activities
mITT
Modifiedintent to treat set
MVPA
Moderate to vigorous physical activity
N/A
Not applicable
PA
Physical activity
PEG
Polyethylene glycol
PMDA
Pharmaceuticals and Medical Devices Agency
PMI
Post-marketing investigation
PT
Preferred term
PTP
Previously treated patient
rFVIII
Recombinant coagulation factor VIII
SAE
Serious adverse event
SAF
Safety analysis set
SAP
Statistical Analysis Plan
SOC
System organ class
TEAE
Treatment-emergent adverse event
WHO-DD
World Health Organization Drug Dictionary


Statistical Analysis Plan
BAY 94-9027 / 19764
Page: 4 of 17
Reference Number: RD-SOP-1119
Supplement Version: 10
1.
Introduction
Recombinant coagulation FVIII (rFVIII) is a replacement therapy in patients with Hemophilia 
A. Jivi (BAY 94-9027) has received marketing authorization amongst others from Food and 
Drug Administration (FDA), European Medicines Agency (EMA), Japanese Pharmaceuticals 
and Medical Devices Agency (PMDA), and Health Canada. The approved indication is: 
Treatment and prophylaxis of bleeding (including perioperative management) in previously 
treated patients (PTPs) ≥ 12 years of age with hemophilia A (congenital FVIII deficiency).
Regulatory requirements necessitate to assess the safety of Jivi in a total of 200 participants 
with 100 exposure days (ED) including pre-licensure participants of the development program 
from the studies 13024 (PROTECT VIII) and 15912 (PROTECT Kids). This study will 
include at least 25 participants for fulfillment of the requirements and provide a pooled 
analysis of all clinical studies (phase III/IV).
The purpose of this statistical analysis plan (SAP) is to describe the procedures and statistical 
methods to be used  in analyzing and reporting results for the assessment of safety and 
efficacy of Jivi in Study 19764 and the integrated analysis of this study together with studies 
13024 Part A (incl. extension) and 15912 (incl. extension).
Relevant documents

Clinical Study Protocol No. BAY 94-9027 / 19764 Version 2.0, dated 04 FEB 2020

Integrated Clinical Study Protocol No. BAY 94-9027 / 13024, version 6.0, dated 20 
JUN 2019 

Statistical Analysis Plan for study 13024, version 7.0, dated 11 SEP 2019

Integrated Clinical Study Protocol BAY 94-9027 / 15912, version 5.0, dated 13 JUN
2017

Statistical Analysis Plan for study 15912, version 3.0, dated 11 SEP 2019
2.
Study Objectives
The objective of the study is to confirm general safety and clinical efficacy with specific focus 
on immunogenicity and inhibitor documentation in a routine clinical use of the product in at 
least additional 25 participants during 100 ED in order to fully comply with Guideline 
requirements of 200 participants observed for at least 100 ED including participants from pre-
authorization studies.


Statistical Analysis Plan
BAY 94-9027 / 19764
Page: 5 of 17
Reference Number: RD-SOP-1119
Supplement Version: 10
Table 2–1: Study objectives and endpoints for study 19764
Objectives
Endpoints throughout the study
Primary

To assess safety of Jivi
Primary Endpoint  

FVIII inhibitor development by the 
Nijmegen Bethesda assay 
Secondary Endpoints

Treatment-emergent adverse events 
(TEAE)

Development of treatment-emergent 
anti-PEG antibodies
Secondary

To assess clinical efficacy of Jivi
Secondary Endpoint

Annualized bleeding rate (ABR) 
Other pre-specified

Number of ED

Percentage of participants with 0 
bleeding events during a 6-month period

Consumption

Bleeding event attributes

Incremental recovery
3.
Study Design
The study will be a multicenter, single group, uncontrolled open label trial. Severe hemophilia 
A patients, age ≥18 years, will be enrolled and treated with prophylaxis treatment and for 
breakthrough bleeds for at least 100 ED, which may require 1-2 years depending on the 
prophylaxis regimen. Assessment of immunogenicity and safety will be performed at pre-
defined ED as required by EMA FVIII Guideline. 
The recommended starting dose is every 5 days treatment (45 IU/kg). An assessment of 
response to treatment will be performed at the next scheduled visit after 10-15 ED (~ 8-10 
weeks). Subsequent dosing depends on need assessed by the investigator according to the 
following scheme and can be  adjusted as needed.


Statistical Analysis Plan
BAY 94-9027 / 19764
Page: 6 of 17
Reference Number: RD-SOP-1119
Supplement Version: 10
Table 3–1: Recommended dose regimen
Procedure
Duration
Dose regimen
Route of 
administration
Screening
> 2 weeks, 
≤ 8 weeks
Continuation of previous treatment
Treatment 
Phase
Time to 
reach 10-
15 ED (~ 8 
to 10 
weeks)
Recommended starting dose 45 IU/kg every 5 
days. Dose regimen can be adjusted any time 
in case of bleeds 
IV injection
Time to 
reach 100 
ED
0 bleeds
during the 
first 8-10 
weeks: 
Recommended dose regimen: 
60 IU/kg every 7 days
IV injection
1 clinically 
relevant 
bleed during 
the first 8-10 
weeks:
Continue every 5 days at dose 
of 60 IU/kg
Or at investigator’s judgement: 
Switch to 40 IU/kg 2x/week 
≥ 2 clinically 
relevant 
bleeds during 
the first 8-10 
weeks:
Change to 40 IU/kg 2x/week
ED = exposure day, IV = intravenous 
Clinically relevant: joint or muscle bleed that needs treatment
The total treatment duration is the time to reach 100 ED of Jivi. The total duration of study 
participation for each participant may require up to 2 years depending on the selected 
prophylactic regimen. When 25 participants have reached 100 ED, the study will be 
completed. Remaining participants may prematurely discontinue with reason ‘Study 
terminated by sponsor’ when a treatment duration of at least 6 months is reached.
4.
General Statistical Considerations
4.1
General Principles
The study is not designed to test any predefined hypothesis. All analyses will be descriptive or 
exploratory.
The statistical evaluation will be performed by using the software package SAS release 9.2 or 
higher (SAS Institute Inc., Cary, NC, USA). All variables will be analyzed by descriptive 
statistical methods. The number of available and missing data, mean, standard deviation, 
minimum, quartiles, median, and maximum values will be calculated for metric data. 
Frequency tables will be generated for categorical data.
In addition to the analyses for study 19764, pooled results across the clinical phase 3/phase 4 
studies will be presented. Therefore, data of study 19764 will be pooled with data from 
studies 13024 and 15912. 
 
Except when mentioned otherwise, all safety analyses will present results for study 19764 and 
pooled results of studies 19764, 13024 Part A (incl. Part A extension) and 15912 (incl. 
CCI


Statistical Analysis Plan
BAY 94-9027 / 19764
Page: 7 of 17
Reference Number: RD-SOP-1119
Supplement Version: 10
extension). All safety analyses will be presented for the combined Jivi treatment group and 
will not distinguish between different regimens or treatment frequencies. 
Efficacy analyses will be done for study 19764. If presented by treatment regimen, this will 
refer to the regimen at Visit 3. Participants who switch their regimen after Visit 3 will be 
assigned to a ‘Variable frequency’ group. Participants who dropped out before Visit 3 will be 
analyzed with their baseline regimen.
In addition to the study specific efficacy analysis, pooled results from studies 19764, 13024 
Part A (incl. extension), and 15912 (incl. extension) for the main efficacy endpoint, i.e. 
annualized bleeding rates (ABR), will be provided. 
Data handling rules described in this SAP refer specifically to study 19764. Data handling
will be consistent with the data handling already applied to studies 13024 Part A and 15912. 
More details about the data handling of studies 13024 Part A and 15912 are available in the 
SAPs of these  studies.
The following subgroup will be analyzed for safety and pooled efficacy:

Age group 1: <12 years vs ≥ 12 years (at enrollment) 
Subgroup tables will not be displayed by study/pool but by subgroup categories instead.
In case of multiple measurements before first treatment, the last one will be analyzed as 
baseline measurement.
4.2
Handling of Dropouts
A participant who discontinues study participation prematurely for any reason is defined as a 
dropout if the participant has already been administered at least one dose of study drug. 
The reasons for  withdrawal will be listed in a table. Dropouts will be included in all safety 
analyses. They will also be included in efficacy analyses if the treatment duration is >= 3 
months. The ABR will be calculated for these participants. It is assumed that a shorter 
treatment duration will not be sufficient to correctly estimate the ABR and would bias the 
results. When calculating ABRs, the end of the measuring period for a dropout is defined as 
the later of last available infusion record from the electronic patient diary (ePD) or the last 
procedure in a scheduled visit, excluding the final visit.
4.3
Handling of Missing Data
All missing or partial data will be presented in the subject data listings as they are recorded on 
the Case Report Form (CRF). 
General rules
When appropriate, the following imputation rules will be implemented so as not to exclude 
participants from statistical analyses due to missing or incomplete data:

Missing time of infusions
If an in-hospital infusion has a missing time, the time of the pre-infusion FVIII level 
measurement plus 1 minute will be used. If this time is also missing, 10:00 will be substituted.

Missing or incomplete adverse event (AE) start date
If first study treatment falls within imputation range, incomplete start date is imputed as first 
day of treatment. Otherwise, it is imputed to the earliest date of the imputation interval. 


Statistical Analysis Plan
BAY 94-9027 / 19764
Page: 8 of 17
Reference Number: RD-SOP-1119
Supplement Version: 10
Empty start date is not imputed. Incomplete stop date is always imputed as the latest date of 
the imputation interval. Empty stop date is not imputed and presumed to be ongoing.

Missing or incomplete concomitant medication start and end date
If first study treatment falls within imputation range, incomplete start date is imputed as first 
day of treatment. Otherwise, it is imputed to the earliest date of the imputation interval. 
Empty start date is not imputed. Incomplete stop date is always imputed as the latest date of 
the imputation interval. Empty stop date is not imputed and presumed to be ongoing.
Partially missing dates of medications categorized as ‘PRIOR FVIII THERAPY’ will not be 
imputed. All these medications will be considered prior medications.
Additional descriptive analyses in the presence of missing data
The number of participants who prematurely discontinue the study for any reason, as well as 
the time point and reasons for premature discontinuation of study, will be reported. The 
number of missing FVIII inhibitor and anti-drug or anti-PEG antibody measurements will be 
provided. 
4.4
Interim Analyses and Data Monitoring
An optional interim analysis might be performed, if needed for regulatory submission or 
publication purposes, after all participants have been treated for 6 months for assessment of 
the main safety (inhibitor development) and efficacy endpoints.
The scope of the interim analysis will depend on its purpose and will be defined in an SAP 
supplement, if needed.
There will be no Data Safety Monitoring Board (DSMB) for this study.
4.5
Data Rules
The following derivation rules will be applied to this study:
Counting of bleeds:

‘All bleeds’ will include all bleeds, regardless of treated or untreated (untreated bleeds 
will only be available from study 19764)

A bleed will be counted as treated bleed if either the flag variable from the diary indicates 
that the bleed was treated or there is a matching infusion for this bleed (regardless of 
product used).
ABR:
	
    = #   ∗ 365.25 ∗ 24 ∗ 60
	
Period is defined as the number of minutes calculated from the date and time of the beginning 
of the evaluation period and the date and time of the end of the evaluation period. 
Evaluation periods for study 19764:

Main efficacy period: Time from injection at visit 3 to end of treatment

Complete study: Time from first injection at visit 2 to end of treatment


Statistical Analysis Plan
BAY 94-9027 / 19764
Page: 9 of 17
Reference Number: RD-SOP-1119
Supplement Version: 10
End of treatment is defined as date of latest infusion plus 7 days or end of study, whatever is 
earlier.
24-hour rule:
All bleeds that occur during the same calendar day will be considered as one bleed. Priority 
will be determined according to the following order:

  - spontaneous bleed

  - joint bleed

  - treated bleed

  - earliest bleed
The analyzed bleed will be the one with the highest priority. It will get the following derived 
characteristics:

  - combination of all types and locations

  - highest treated status (i.e. treated if at least one bleed on that day is treated)

  - worst assessment of hemostasis 
All other bleeds on the same calendar day will not be considered for analysis but only listed.
72-hour rule:
A spontaneous joint or spontaneous muscle bleed will not be counted if it occurs within 72 
hours of a bleed (or infusion for that bleed) at the same site. For a spontaneous bleed to be 
affected by this rule, all sites listed on the bleed must also be specified in the previous bleeds 
during a 72 hour time frame. Infusions for such bleeds will be considered to be follow-up 
infusions. If the current and previous bleeds are both skin/mucosa bleeds, this rule does not 
apply. The rule operates with date/time and bleed locations adjusted by 24-hour rule. Bleeds 
eliminated by 24-hr rule are not considered.
Joint bleed:
Joint bleeds can occur in more than 1 joint site. When counting sites for the joint bleeds, all 
sites will be counted. Data reflecting joint site frequencies will include the frequencies over 
all sites. 
Incremental recovery:
FVIII levels measured by the chromogenic assay will be analyzed.
Incremental recovery is calculated as shown below:
Incremental recovery = (post-infusion FVIII level – pre-infusion FVIII level ) * weight / dose 
(in IU)
The most recent weight measurement at time of blood sampling will be used for calculation.
If a FVIII level value is below the lower limit of quantification (LLOQ), a data point with the 
value of one-half the LLOQ will be substituted.


Statistical Analysis Plan
BAY 94-9027 / 19764
Page: 10 of 17
Reference Number: RD-SOP-1119
Supplement Version: 10
Participants with positive FVIII inhibitor or any positive anti-drug antibody measurement 
during study will be excluded from recovery analyses. Results of these participants will be 
listed.
A validity flag for incremental recovery values will be created.  All incremental recoveries 
will be considered valid except when the following conditions apply:

Pre-infusion FVIII level is equal to or higher than the post-infusion FVIII level

Post-infusion FVIII value is below the LLOQ

The time from previous study drug infusion to the pre-infusion FVIII level measurement 
is less than 72 hours (i.e. protocol defined wash-out period of 72 hours was not kept)
If an incremental recovery is flagged as not valid, then the corresponding pre-infusion, post-
infusion and incremental recovery value will not be considered in tables displaying summary
statistics of incremental recovery values and FVIII levels. FVIII levels that are not valid for 
calculation of incremental recovery will be listed.
Medical history groupings:
‘Medical history of HIV’ will be defined as the occurrence of at least one of the medical 
history preferred terms ‘HIV infection’, ‘HIV disease’, and ‘HIV test positive’.
‘Medical history of hepatitis C’ is given if at least one of the preferred terms ‘Hepatitis C’, 
‘Chronic hepatitis C’, ‘Hepatitis C virus test positive’, ‘Hepatitis C antibody positive’, 
‘Hepatitis C infection’, ‘Hepatitis C chronic’ is reported in the medical history data.
‘Medical history of arthropathy’ will be defined as the occurrence of at least one of the 
medical history preferred terms ‘Arthropathy’ and ‘Haemophilic arthropathy’.
Compliance:
Compliance of each patient will be calculated as:
Compliance (%) based on prophylaxis infusion count = 100 * number of actual prophylaxis 
infusions / number of expected prophylaxis infusion
Compliance (%) based on total infusion count = 100 * number of actual infusions / number of 
expected prophylaxis infusion
Number of expected prophylaxis infusions: Number of prescribed infusions per week / 7 * 
period of prescribed frequency (days)
Treatment administration:
Documented infusions with other FVIII products or with a dose of 0 IU will be excluded. 
Infusions with a missing dose will be counted for number of infusions and exposure days but 
will be excluded from other treatment administration analyses.


Statistical Analysis Plan
BAY 94-9027 / 19764
Page: 11 of 17
Reference Number: RD-SOP-1119
Supplement Version: 10
4.6
Blind Review/Validity review
The results of the  final  data assessment will be documented in the final list of important 
deviations, validity findings and assignment to analysis set(s). Any changes to the statistical 
analysis prompted by the results of the  review  of study data will be documented in an 
amendment and, if applicable, in a supplement to this SAP.
5.
Analysis Sets
5.1
Assignment of analysis sets
Final decisions regarding the assignment of participants to analysis sets will be made during 
the review of study data and documented in the final list of important deviations, validity 
findings and assignment to analysis sets (see section 4.6).
Safety analysis set (SAF)
A participant will be included in the SAF if he received at least 1 infusion of study drug.
Intent to treat set (ITT)
A participant will be included in the ITT if he received at least 1 infusion of study drug and 
has any injection/bleeding data available.
Modified Intent-to-treat set (mITT)
A participant will be included in the mITT if he received at least 1 infusion of study drug and 
has injection/bleeding data for at least 3 months available. 
A participant of study 13024 or study 15912 will only be included in the mITT if he entered 
the extension phase of the study.  
6.
Statistical Methodology
6.1
Population characteristics
All tables will be provided for the SAF and the mITT. 
Demographics will include age, ethnicity, race, weight, height and BMI.  
Baseline characteristics will include age at first treatment, type of first treatment regimen, 
type of FVIII gene mutation, family history of hemophilia, family history of inhibitor, 
presence of target joint, frequencies for specific target joints, previous FVIII treatment type, 
prior hemophilia treatment drug, medical history of concomitant diseases (e.g. HIV, hepatitis 
C, arthropathy, hypertension).
Summary statistics will be provided for number of bleeds and number of joint bleeds during
the last 12 months prior to study and will be stratified by previous treatment type. 
Descriptive statistics will be provided for the baseline activity level and previous dosing 
frequencies and dosages of study 19764.
Medical history, concomitant medication use
Medical history data as coded by MedDRA will be summarized by primary system organ 
class (SOC) and preferred term (PT). Prior and concomitant medications as coded by WHO-


Statistical Analysis Plan
BAY 94-9027 / 19764
Page: 12 of 17
Reference Number: RD-SOP-1119
Supplement Version: 10
DD will be summarized by ATC class and subclass. Medications taken before start of study 
drug will be considered prior medications, medications taken within the treatment period will 
be considered concomitant medications. 
New concomitant medications that started after first treatment and belong to the ATC 
subclasses ‘ANTIHEMORRHAGICS’, ‘BLOOD SUBSTITUTES AND PERFUSION 
SOLUTIONS’, and ‘ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS’ will 
be presented by ATC subclass and standardized medication name. Factor VIII medications 
will be identified and grouped. A listing of new concomitant medications stratified by 
‘Antihemorrhagics’, ‘Blood substitutes and perfusion solutions’, and ‘Antiinflammatory and 
antirheumatic products’ will be provided for study 19764.
Exposure and treatment duration
Number of EDs and time in study will be analyzed by summary statistics. Number of EDs
will be categorized into < 50 ED vs >= 50 - < 100 ED vs >= 100 ED. One ED is defined as a 
calendar day during which at least one infusion is taken by the participant. 
Compliance
Summary statistics for compliance (%) and time between prophylaxis injections (days) will be 
presented. Calculation of compliance is described in section 4.5.
Compliance will be categorized into < 95%, >= 95% - <= 105%, > 105%.
6.2
Efficacy
The secondary objective of the study is to assess clinical efficacy. Unless otherwise 
mentioned, all efficacy analyses will be performed on the mITT population with a treatment 
period of at least 3 months. A comprehensive efficacy analysis will be done for study 19764. 
In addition, pooled results will be provided for the ABR.
The following descriptions refer to the analysis for the individual study data of 19764.
ABR:
The ABR is the main efficacy endpoint of the secondary objective. 

ABRs will be presented for all bleeds, joint bleeds, spontaneous bleeds, , and trauma
bleeds

Results for the main efficacy period (Visit 3 to end of study) will be displayed by 
treatment regimen as described in section 4.1

Results for the complete study period (baseline to end of study) will be shown for the 
combined prophylaxis group
Other efficacy endpoints
Unless otherwise mentioned, results will be presented for complete study periods.

Percentages of participants with 0 bleeds, 0 joint bleeds, 0 spontaneous bleeds, during 
the following treatment periods: 
o
Last 6 months
o
Last year


Statistical Analysis Plan
BAY 94-9027 / 19764
Page: 13 of 17
Reference Number: RD-SOP-1119
Supplement Version: 10
!
Treatment administration (overall, prophylaxis, treatment of bleeds): number of 
infusions (all and per year), consumption (IU, IU/kg, IU/kg/year, IU/kg/infusion, 
IU/year, IU/infusion)
!
Reason for infusion 
!
Bleeding attributes: type, location, intensity, number of infusions to control, response 
to treatment
!
FVIII levels pre- and post-infusion and incremental recovery: Results will be 
displayed by visit and overall (means per participant across visits) 
!
Pre- and post-infusion FVIII levels which are invalid for the calculation of recovery 
will be listed
!
Bleeds into pre-existing target joints (annualized number, proportion of participants 
with 0 such bleeds) for the complete study period as well as the main efficacy period 
(starting with Visit 3)
!
All untreated bleeds of study 19764 will be listed.
!
Dosing regimens at baseline, Visit 3, and end of study will be compared in shift tables
!
All dosing frequencies, planned doses, and reasons for dose modifications will be 
listed
Pooled efficacy analysis:
Pooled ABRs will be presented for the combined prophylaxis group and complete study 
periods. Only subjects who participated in the extension periods will be included in the 
analysis. Participants from study 13024 who only received on-demand treatment will be 
excluded from the pooled efficacy analysis because on-demand treatment was not applied in 
the other studies and pooling of on-demand and prophylaxis participants is not meaningful for 
efficacy endpoints. Participants who switched from on-demand treatment in the main study to 
prophylaxis in the extension part of study 13024 will be included in the prophylaxis group 
with their prophylaxis treatment period. The on-demand main study part of these participants 
will not be included in the analysis. Results will be dispayed by age group.
Sensitivity analyses: 
!
Estimates and 95% confidence intervals from a negative binomial regression model
will be presented for the ABRs of all bleeds, different lengths of evaluation periods 
will be addressed via an offset variable 
!
A subject listing including number and kind of bleeds and time in study will be 
provided for participants excluded from the mITT set
CCI


Statistical Analysis Plan
BAY 94-9027 / 19764
Page: 14 of 17
Reference Number: RD-SOP-1119
Supplement Version: 10
6.3
Pharmacokinetics/pharmacodynamics
Pharmacokinetic and pharmacodynamic parameters are not evaluated in this study.
6.4
Safety
All safety analyses will be performed on the SAF. MedDRA codes of studies 13024 and 
15912 will be updated by the MedDRA version used for study 19764. An AE will be 
considered treatment-emergent if it starts after first injection and not later than 7 days after 
last injection of Jivi.
Overview tables displaying all AEs, all pre-treatment AEs and all treatment emergent adverse 
events (TEAEs) will be created. All subsequent tables will be presented by MedDRA 
preferred term (PT) and system organ class (SOC). Serious AEs, TEAEs, serious TEAEs, 
drug-related TEAEs, serious drug-related TEAEs, TEAEs of special interest, TEAEs causing 
discontinuation of study drug, TEAEs by maximum intensity, drug-related TEAEs by 
maximum intensity, non-serious TEAEs, and AEs leading to death will be presented. 
Overview tables, all TEAEs, serious TEAEs, drug-related TEAEs and serious drug-related 
TEAEs will be displayed by subgroups.
Factor VIII inhibitor, PEG antibody and BAY 94-9027 antibody results
Frequency tables will be provided for the number of participants with confirmed inhibitors 
and anti-drug and anti-PEG antibodies. The status during study will be displayed by pre-
treatment status. Proportion of participants with positive measurements at the end of the 
observation period will be displayed based on the number of participants with positive status 
during study. 
Inhibitors will be classified as being either low titer (≥0.6 BU/mL and ≤5 BU/mL) or high 
titer (>5 BU) based upon persistence of an inhibitor.
Antibody incidences at screening/baseline as well as new antibody incidences after start of 
treatment will be presented.
CCI


Statistical Analysis Plan
BAY 94-9027 / 19764
Page: 15 of 17
Reference Number: RD-SOP-1119
Supplement Version: 10
Subject listings will be provided for all participants from study 19764 with at least one 
positive FVIII inhibitor measurement/BAY 94-9027 antibody measurement/PEG antibody 
measurement/PEG IgM antibody measurement showing all FVIII inhibitor/BAY 94-9027 
antibody/PEG antibody/PEG IgM antibody (respectively) laboratory measurements as well as 
FVIII recovery results of these participants, including the number of ED before the 
measurement dates and the date of the last injection before measurement dates. 
All measurement results for inhibitors including repeated measurements in case of positive 
results will be displayed by time point and presented in subject listings. 
Clinical laboratory
Number of participants with treatment emergent high and low laboratory abnormalities will 
be displayed in frequency tables by laboratory category. 
Summary statistics for all laboratory values at baseline and individual last visit will be 
presented. Changes from baseline at last visit will be provided, if applicable.
Shift tables for urinalysis parameters will be shown.
In addition, summary statistics for all laboratory values and changes from baseline by visit 
will be displayed for study 19764. 
Laboratory results will not be displayed by subgroups.
Vital signs
Summary statistics including changes from baseline will be presented for vital signs (systolic 
blood pressure, diastolic blood pressure, heart rate, temperature) by visit for study 19764. 
Vital signs will not be stratified by subgroups.
COVID-19 pandemic
Subjects affected by the COVID-19 pandemic related study disruptions and important 
protocol deviations associated with the COVID-19 pandemic will be listed.


Statistical Analysis Plan
BAY 94-9027 / 19764
Page: 16 of 17
Reference Number: RD-SOP-1119
Supplement Version: 10
7.
Document history and changes in the planned statistical analysis
This SAP is based on the protocol Version 2.0 dated 04 FEB 2020. 
SAP 
Version
Date
Change
Rationale
1
03 SEP 2019
Not applicable
Original version
2
14 MAR 2022
Data display
Safety results will be displayed for study 19764 
and pooled, instead of by study and pooled. 
By-study display for 13024 and 15912 would 
be a repetition of already available results.
Scope of efficacy 
analyses.
Main focus was changed from the pooled 
efficacy to the individual study efficacy 
analysis. Only ABRs will presented across 
studies. Reason for including pooled results is 
the requirement to provide pooled safety data 
to the authority. Pooled efficacy results are not 
required. Also, there are differences in study 
design which would impact pooled efficacy 
outcomes.
Number of subgroups 
reduced
Results will only be stratified by age < 12 years 
vs >= 12 years. Other subgroup analyses are 
only of interest for publication purposes and will 
be as post-hoc analyses.
Adaption of data rules
Minor changes in descriptions for consistency 
with standard macros and standard 
approaches applied. Details for validity of 
recovery results were specified.
All bleeds will be 
analyzed
Treated bleeds will not be analyzed separately 
due to the low number of such 
bleeds.Analyzing all bleeds is considered 
conservative.
 
 
 
 
 
CCI
CCI


Statistical Analysis Plan
BAY 94-9027 / 19764
Page: 17 of 17
Reference Number: RD-SOP-1119
Supplement Version: 10
8.
References
Not applicable.